Gold nanoparticles for plasmid delivery by Almeida, Ana Catarina Couto
 
 
Ana Catarina Couto Almeida 
 
Licenciada em Química Aplicada 
 
  
  
  
  
    
  
 
Gold Nanoparticles for Plasmid Delivery 
  
 
 
  
 
Dissertação para obtenção do Grau de Mestre em Bioquímica 
 
  
  
  
  
Orientadora: Rita Cabral, Postdoctoral Research Fellow, FCT-UNL 
Co-orientador: Pedro M. R. Viana Baptista, Professor Associado 
com Agregação, FCT-UNL 
  
  
  
 
 
  
 Júri: 
 
 
Presidente: Prof. Doutor José Ricardo Ramos Franco Tavares 
Arguente: Doutora Inês Isabel Fernandes Gomes 
Vogal: Prof. Doutor Pedro M. R. Viana Baptista 
 
 
   
  
  
  
 
Setembro 2014 
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
 
 
Gold Nanoparticles for Plasmid Delivery 
 
 
 
 
 
 
Copyright Ana Catarina Couto Almeida, FCT/UNL, UNL 
 
 
 
 
 
 
 
 
 
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo 
e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares 
impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou 
que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua 
cópia e distribuição com objectivos educacionais ou de investigação, não comerciais, desde 
que seja dado crédito ao autor e editor. 
 
 
 
iv 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
v 
 
RESUMO 
 
A terapia génica representa uma estratégia ideal para o tratamento de doenças genéticas e 
adquiridas, como o cancro, e tipicamente envolve a inserção de um gene funcional em células 
para corrigir uma disfunção celular ou para fornecer uma nova função. Os sistemas de 
transporte de ácidos nucleicos são baseados em dois modelos: vectores virais e não virais. Os 
primeiros apresentam uma alta eficiência na entrega do material genético mas a sua maior 
barreira é a imunogenicidade. Uma vez que os vectores não virais não apresentam 
imunogenicidade, estes têm sido amplamente estudados. As nanopartículas de ouro têm sido 
propostas como óptimos sistemas de entrega de material genético, devido ao seu tamanho 
reduzido, elevado rácio superfície-volume e capacidade de serem funcionalizadas com várias 
moléculas. No presente trabalho desenvolveu-se uma formulação baseada em nanopartículas 
de ouro para transporte de um plasmídeo, contendo como gene repórter um gene codificante 
da proteína verde fluorescente, numa linha celular de cancro colo-rectal. O sistema de entrega 
resultou da funcionalização de AuNPs de 14 nm com uma múltipla camada de PEG (4300114 
cadeias de PEG/AuNP), aumentando a estabilidade e a biocompatibilidade das AuNPs; 
amónios quaternários que providenciam cargas positivas que permitem a ligação 
electroestática do plasmídeo, que é considerado o agente terapêutico que se pretende 
transportar para dentro das células. O sistema desenvolvido foi caracterizado por 
espectroscopia de UV-vis, DLS, TEM e análise electroforética em gel de agarose, tendo-se 
produzindo um sistema com um diâmetro de 113.5 nm. A eficiência da transfecção celular com 
o sistema desenvolvido foi avaliada por PCR e pela expressão da proteína verde fluorescente 
(enhanced green fluorescente protein, EGFP), através de espectroscopia de fluorescência e 
microscopia de fluorescência. Verificou-se que a internalização do sistema ocorre após 3h de 
incubação, no entanto observou-se um nível residual de expressão da proteína. Depois de 24h 
de incubação, a expressão aumentou 3 vezes em relação às células não transfectadas. O 
sistema comercial (Lipofectamine) expressou 5 vezes mais EGFP do que o sistema 
desenvolvido AuNP@PEG@R4N
+
@pEGFP. Esta diferença poderá estar relacionada com a 
menor translocação para o núcleo. 
 
Termos chave: nanopartículas de ouro, bioconjugação, nanotransportador, terapia génica, 
DNA plasmídico, cancro 
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ABSTRACT 
 
Gene therapy presents an ideal strategy for the treatment of genetic as well as acquired 
diseases, such as cancer and typically involves the insertion of a functioning gene into cells to 
correct a cellular dysfunction or to provide a new cellular function. Gene delivery vectors are 
based in two models: viral and non-viral. Viral vectors have high transfection efficiency but their 
major barrier is immunogenicity. Since the non-viral vectors have no immunogenicity, these 
have been widely studied. Gold nanoparticles have been proposed as optimal delivery systems 
of genetic material, due their small size, high surface-to-volume ratio and the ability to be 
functionalized with multiple molecules. In the present work, an AuNP-based formulation was 
developed to deliver a plasmid in a colorectal cancer cell line, containing as reporter gene the 
gene encoding to EGFP. The delivery system resulted from the functionalization of 14 nm AuNP 
with a PEG layer (4300114 PEG chains/AuNP), which increases stability and biocompatibility 
of AuNPs; quaternary ammonium groups which provide positive charges that allow electrostatic 
binding of plasmid, which is considered the therapeutic agent to be transported into cells. The 
system developed was characterized by UV-vis spectroscopy, DLS, TEM and by electrophoretic 
mobility, yielding a formulation with 113.5 nm.Transfection efficiency of the formulation 
developed was evaluated through PCR and through EGFP expression by fluorescence 
microscopy and fluorescence spectroscopy. The internalization was observed 3h post 
transfection; however a low level of EGFP expression was achieved. After 24h of incubation, 
EGFP expression increases just 3 times compared to non-transfected cells. The commercial 
system (Lipofectamine) expressed EGFP 5 times more than the system developed 
AuNP@PEG@R4N
+
@pEGFP. This difference could be related to lower translocation to the 
nucleus. 
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1. INTRODUCTION 
 
1.1 CANCER: AN OVERVIEW 
 
Cancer is one of the leading causes of mortality in the modern world, with more than 10 million 
new cases every year. According to GLOBOCAN 2012, the three types of cancer with the 
highest incidence at a global level are the breast, lung and colorectal cancers, while the highest 
mortality rate is associated with lung, colorectal and stomach cancers [GLOBOCAN, 2012]. 
Cancer is defined as a multifactorial disease characterized by uncontrolled growth and spread 
of abnormal cells. Behind the origin of cancer are factors that can be internal, such as inherited 
mutations, hormones, immune conditions, and mutations that occur from metabolism and 
external factors like tobacco, infectious organisms, chemicals, and radiation (Cancer Facts & 
Figures 2014). 
 
The main characteristic common to different types of cancer are proliferative signaling, evasion 
of growth suppressors, resistance to cell death, replicative immortality, angiogenesis, invasion 
and metastasis (Hanahan & Weinberg 2011). 
 
1.1.1 CURRENT NEEDS 
 
The potential to provide new targets and strategies for cancer therapy lies in understanding 
cancer biology. A huge amount of research has already been carried out, resulting in a number 
of available treatments. Currently, the most common therapies include surgery, radiation, 
chemotherapy, hormone therapy, biological therapy, and targeted therapy (Cancer Facts & 
Figures 2014). 
 
However, these available treatments are limited because the agents used do not differentiate 
between cancerous and normal cells, causing toxicity to healthy cells, severe side effects and 
eventually multiple drug resistance. Thus, the main goal in cancer treatment is to develop a 
therapeutic system that takes advantage of the potency of therapeutic agents by more 
effectively targeting them to tumor tissues (Liu et al. 2007, Nazir et al. 2014) 
 
1.2 GENE THERAPY 
 
Many human diseases result from genetic mutations, including deletions and insertions, which 
lead to disorders in metabolic pathways, ligand/receptor function, cell cycle regulation, cell 
skeleton or extra-cellular protein structure and function. Generally, gene therapy approaches 
are based on the employment of genetically engineered vectors that promote the transfer of 
nucleic acids into cells in order to regulate, repair, replace, add or delete a genetic sequence 
(Cevher et al. 2012, Gascón et al. 2013, Kaliberov & Buchsbaum 2012, Liu & Zhang 2011). 
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An ideal gene delivery system should be stable, biocompatible, nontoxic, present lack of 
immunogenicity, capable of highly efficient transport of exogenous genetic material into their 
target sites, resistant to premature degradation and capable of modulation of gene expression 
for a desired period of time (Jones et al. 2013, Liu & Zhang 2011). 
Nucleic acids have been explored to treat various diseases, such as cancer, genetic disorders, 
infections and cardiovascular diseases. Thus, gene therapy involves the use of nucleic acid as 
therapeutics agents, such as plasmid DNA (pDNA), oligonucleotides, small interfering RNA 
(siRNA), aptamers, Ribozymes or DNAzymes. 
 
Plasmid vectors are high molecular weight, double-stranded DNA constructs containing 
transgenes, which encode specific proteins. In the early stages of development, plasmid-based 
gene therapy can be employed to correct inheritable disorders resulting from a single gene 
defect. Gene therapy using plasmid DNA is based on the introduction of the pDNA, encoding a 
therapeutic gene sequence, into the nucleus of the target cells to express functional proteins, 
through transcription and translation (Liang & Lam 2012, Pushpendra et al. 2012). The 
mechanism of action of plasmid DNA involves the entry of plasmid molecules into the nucleus 
after entering the cytoplasm. The entry of plasmid molecules into the nucleus through the 
nuclear pore complexes is an extremely challenging and difficult process that controls the 
efficiency of gene expression (Patil et al. 2005, Pushpendra et al. 2012). Gene expression is 
also controlled by regulatory signals such as the promoter and enhancer sequences. Promoter 
sequences initiate the transcription process by acting as a recognition site for the RNA 
polymerase. Higher efficiency can be obtained by engineering the plasmid with strong tissue- or 
tumor-specific promoters (Elsabahy et al. 2011). 
 
Another approach for induction of transgenes is suicide gene therapy. This method involves the 
stable transfection of chemosensitization genes in tumor cells, which upon gene expression 
convert a separately administered, nontoxic pro-drug into a chemotoxic drug. Since only the 
transfected tumor cells are capable of this intracellular conversion, only these cells are 
susceptible to the chemotoxic entity (Patil et al. 2005). 
 
Oligonucleotides are another type of nucleic acid that can be used as therapeutic agent. 
Oligonucleotides are short single-stranded segments of DNA (12 – 28 bases) that can 
selectively inhibit the expression of a single gene. Two approaches are used with 
oligonucleotides, antisense and antigene. The first involves the interaction of oligonucleotides 
with mRNA, forming a duplex, inhibiting their translation or processing and consequently 
inhibiting protein expression. The antigene approach requires the entry of oligonucleotides into 
the nucleus and the insertion between double strands of genomic DNA to form a triple-helix 
structure, preventing the transcription and subsequent translation of the gene. 
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Another gene therapy approach involves the delivery of small interfering RNA (siRNA). This is 
used as posttranscriptional mechanism of gene silencing. Typically, these are short double-
stranded RNA segments with 21–23 nucleotides, namely the guide strand and passenger 
strand, the former of which is complementary to the target mRNA sequence of the gene whose 
translation is to be blocked. The mechanism of action involves the incorporation of the siRNA 
guide strand into RNA-induced silencing complexes (RISCs), which bind to the mRNA of 
interest and stimulate mRNA degradation mechanisms, such as nuclease activity, that lead to 
silencing of the particular gene. This approach using siRNAs is more promising than antisense 
oligonucleotides due their high degree of specificity to mRNAs. Furthermore, this technology 
has a more rapid development that oligonucleotides or plasmid DNA, because siRNAs does not 
have to enter the nucleus for their activity and require less refined delivery systems (Patil et al. 
2005, Pushpendra et al. 2012). 
 
Aptamers are another class of nucleic acids used in gene therapy. These are single stranded 
oligonucleotides (RNA or DNA) that recognize their targets on the basis of shape 
complementarity. The mechanisms of action are different from other oligonucleotides because, 
while some oligonucleotide therapies interfere with the translational machinery, aptamers target 
proteins directly and bind to them, altering their function. Their behavior is similar to antibodies 
and is preferred over antibodies in protein inhibition due their specificity and nonimmunogenicity 
(Prasad & Roy 2008, Pushpendra et al. 2012) 
 
The last type of gene therapy agents are ribozymes. These are RNA enzymes that are capable 
of sequence specific cleavage of mRNA molecules, resulting in selective inhibition of expression 
of deleterious genes. In their mechanism of action, a ribozyme binds specifically to an mRNA 
strand and cleaves it, preventing its translation. After cleavage, the enzyme is released and is 
ready for binding and destroying another mRNA molecule, leading to highly specific knockdown 
of the target genes. The presence of the RNA backbone in ribozymes makes them biologically 
unstable in vivo because these are easy targets for degradation by RNases (Prasad & Roy 
2008, Pushpendra et al. 2012). 
 
Another type of nucleic acid enzymes are DNAzymes. They are analogs of ribozymes with 
greater biological stability because the RNA backbone chemistry is replaced by the DNA motifs 
that confer improved biological stability (Patil et al. 2005). 
 
The focus of this work is the delivery of plasmid DNA. Until now, there are no plasmid DNA 
based therapeutic products approved by the FDA due the lack of an efficient and safe delivery 
system, which limits the clinical application of nucleic acids (Liang & Lam 2012). However, there 
are two methods that have been used in gene therapy clinical trials using non-viral vectors: one 
involves the injection of naked plasmid DNA into a tissue. This has been used in ~14% of 
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approved clinical trials. The other method is transfection of plasmid DNA using liposomes and 
has been used in ~9% of approved trials (Cotrim & Baum 2008). 
 
1.2.1 GENE DELIVERY SYSTEMS 
 
Gene delivery systems can be divided in viral and non-viral systems. Viral vectors consist of 
viruses that are genetically engineered to be replication-deficient. They are the most effective 
but their immunogenicity, oncogenicity, small size of the DNA they can transport and the difficult 
optimization in large-scale production limit their applications. Non-viral have gain more attention 
due their favorable properties, including lack of immunogenicity, low toxicity, potential for tissue 
specificity, large gene insert size and they are low cost and more reproducible. The main 
limitation of non-viral systems is their low transfection efficiency. Currently, viral vector has 
dominated the clinical trials in gene therapy for its relatively high delivery efficiency, as show in 
Figure 1.1, standing out the adenovirus with 23.4%, the retrovirus with 19.2% and plasmid DNA 
with 17.8% (Gascón et al. 2013, Kaliberov & Buchsbaum 2012, Liu & Zhang 2011). 
 
 
Figure 1.1 - Current gene delivery vectors in clinical trials 
(http://www.wiley.com//legacy/wileychi/genmed/clinical/). 
 
Non-viral gene delivery systems were developed as an alternative to viral-based systems. They 
can be divided into physical methods where a physical force is applied to increase permeability 
of the cell membrane and chemical methods that use natural or synthetic carriers to delivery 
genes into the cell (Cevher et al. 2012). 
 
1.2.1.1 NON-VIRAL GENE DELIVERY SYSTEMS 
 
Nucleic acids are incapable of crossing the plasma membrane due their large size and 
hydrophilic nature, due to their negatively charged phosphate groups, and they are very 
susceptible to nuclease degradation. As such, is necessary to develop delivery systems and 
physical methods that facilitate gene transfer to target cells without degradation of the delivered 
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gene, promote cellular uptake, release nucleic acids into the cytoplasm and promote nuclear 
entry (for pDNA delivery). Physical and chemical methods can help delivery systems to cross 
plasma membrane in in vitro and ex vivo applications. Numerous non-viral delivery systems 
have been developed and widely studied during the past years, as show in Table 1.1 (Chou et 
al. 2011, Liang & Lam 2012). 
 
The most well studied non-viral gene delivery systems are cationic polymers and cationic lipids. 
 
Table 1.1 – Current non-viral delivery systems (Al-Dosari & Gao 2009, Cevher et al. 2012, Gascón et al. 
2013, Wang et al. 2013).  
 Method Brief description Advantages Limitations 
C
h
e
m
ic
a
l 
m
e
th
o
d
s
 
Cationic Polymers 
 
 
 
 
 
Cationic Lipids 
 
 
 
Inorganic 
nanoparticles 
Condense DNA into small 
particles protecting it from 
degradation 
 
 
 
Condense DNA into 
cationic particles protecting 
it from degradation 
 
Nanostructures varying in 
size, shape and porosity, 
which can 
be engineered 
Easy to be prepared 
and chemically 
modified, low cost, 
highly 
effective 
 
Easy to be prepared, 
low cost, highly 
effective in vitro 
 
Easily prepared and 
surface-functionalized, 
low toxicity and good 
storage stability 
Toxicity. Some 
polymers are 
non-
biodegradable. 
 
 
Toxicity, low 
efficiency in vivo 
 
 
in vivo 
applications are 
limited by the lack 
of extensive 
studies 
P
h
y
s
ic
a
l 
m
e
th
o
d
s
 
Needle injection 
 
 
 
Gene Gun 
 
 
 
 
Electroporation 
 
 
 
 
 
Sonoporation 
 
 
 
Photoporation 
 
 
 
 
Magnetofection 
 
 
 
 
Hydrodynamic gene 
delivery 
Localized injection of 
naked DNA into muscle or 
skin 
 
DNA-coated gold particles 
are propelled against cells 
 
 
 
Use an electric field to alter 
the cell permeability 
 
 
 
 
Use ultrasounds to 
permeabilize the cell 
membrane 
 
Use a single laser pulse to 
alter the cell permeability 
 
 
 
Use a magnetic field to 
promote DNA transfection 
which is complexed with 
magnetic nanoparticles 
 
Employs the high pressure 
as a driving force for gene 
transfer 
Simple and safe 
 
 
 
Allows delivering 
precise DNA doses; 
safe 
 
 
Effective, reproducible, 
able to transfer large 
size DNA 
 
 
 
Non evasive, site-
specific 
 
 
Selectivity; high 
transfection 
 
 
 
Non-invasive; Low-
dose requirements and 
allow magnetic 
targeting 
 
Highly effective, 
reproducible, simple 
Low efficiency 
 
 
 
Tissue damage 
 
 
 
 
Inaccessible to 
internal organ; 
DNA stability is 
influenced by 
high voltage 
 
Low efficiency 
 
 
 
Further studies 
are needed to 
become 
applicable 
 
Toxicity 
 
 
 
 
Large injection 
volume restricts 
its clinical 
application 
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1.2.2 BARRIERS FOR NON-VIRAL GENE DELIVERY METHODS 
 
The inefficiency of gene delivery primarily results from the inability of the vectors to surpass the 
inumerous barriers encountered from the site of administration to localization in the cell nucleus. 
Generally, the barriers can be divided into extracellular and intracellular. Extracellular barriers 
are characterized by vector stability, blood components and opsnization and last endothelial 
barriers, such as blood brain barrier, vitreous humor, respiratory mucus. 
 
A prerequisite for efficient gene transfer is the delivery of nucleic acids from outside the cell to 
the nucleus. However, for gene delivery in particular, intracellular barriers represent an extra 
concern when designing the formulation. There are four major intracellular barriers: 
1. Cellular binding 
2. Cellular uptake 
3. Endosomal escape 
4. Nuclear entry 
 
 
Figure 1.2 – Barriers and intracellular trafficking of plasmid DNA. The first step is the complexation of DNA 
with the delivery vector; DNA can be internalized via receptor-mediated pathways, including endocytosis, 
or by receptor-independent mechanisms. Once inside the cells the vector needs to escape from the 
endosome, cross the cytoplasm, the DNA needs dissociate from the vector and reach into the nucleus 
where it can be transcribed (Liu & Zhang 2011). 
 
As mentioned above, the first barrier is crossing the cell membrane, a lipid dynamic bilayer that 
regulates the transportation of ions, nutrients, and wastes. This step is considered one of the 
most critical for efficient DNA transfection. Non-viral vectors can interact with the cell membrane 
by electrophilic attraction between the cationic vectors and the highly anionic cell membrane 
surface proteoglycans. In order to improve transfection efficiency, non-viral vectors can be 
conjugated with a specific ligand allowing delivery to a specific cell type. Peptides, proteins, 
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carbohydrates and small molecules have been used to induce target cell-specific internalization 
(Al-Dosari & Gao 2009, Gascón et al. 2013, Liu & Zhang 2011). 
 
Commonly, internalization is achieved by endocytosis. During this process, some part of the 
plasma membrane surrounds the vector and engulfs into a vesicle that then pinches off from the 
cell membrane, enters the cytosol and cross into the cell to its intracellular target.  Endocytosis 
is divided into phagocytosis (the uptake of large particles) and pinocytosis (the uptake of fluids 
and solutes). While phagocytosis is restricted to specialized phagocytes such as macrophages, 
neutrophils and monocytes, pinocytosis occurs in all types of cells. Pinocytosis is divided in four 
classes: (i) clathrin-mediated endocytosis; (ii) caveolae-mediated endocytosis; (iii) 
macropinocytosis; (iv) clathrin- and caveolae- independent endocytosis (El-Sayed & Harashima 
2013, Khalil et al. 2006, Liu & Zhang 2011). 
 
The transfection efficiency of nucleic acid delivery systems is correlated not only with the level 
of cellular uptake but also with their ability to escape from endosomal compartments. Once 
inside the cells, delivery vectors tend to be trapped in the early endosome, where the pH drops 
from neutral to around pH 6 and then traffic through the cell (Liang & Lam 2012, Liu & Zhang 
2011).The evolution of endosomes into late endosomes and lysosomes (the main degradative 
compartments in the cell) is characterized by rapid acidification from pH 6 to 4 within the vesicle 
and recruitment of degradative enzymes into the vesicle to digest vesicular content. Therefore, 
gene escape from the endolysosomal network becomes a very important limiting step in 
achieving an effective gene therapy (Chou et al. 2011, Liang & Lam 2012). 
 
Several approaches have been developed to promote early endosomal escape of non-viral 
gene delivery systems and many hypotheses have been suggested to explain these processes. 
One of the hypotheses, proposed for cationic polymers and dendrimers, is the proton-sponge 
effect. However, this hypothesis is also applied to nanoparticles, since these can be coated with 
high pH buffering capability peptides that undergo structural deformation under acidic pH to 
disrupt the vesicle membrane. During the maturation of endosomes, the membrane-bound 
ATPase proton pumps actively translocate protons from the cytosol into the endosomes, leading 
to the acidification of endosomal compartments (Figure 1.3). At this stage, polymers with the 
‘proton sponge’ property will become protonated and resist the acidification of endosomes. As a 
result, more protons will be continuously pumped into the endosomes with the attempt to lower 
the pH. The proton pumping action is followed by passive entry of chloride ions, increasing ionic 
concentration and leading to water influx. Eventually the osmotic pressure causes swelling and 
rupture of endosomes, releasing their entrapped material (Liang & Lam 2012). 
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Figure 1.3 – Endosomal escape by the ‘‘proton-sponge effect’’. During maturation of endosome, pH 
decrease from 6 to 4. The protons pumps pump H
+
 ions inside the endosome. These protons are 
sequestered by the entrapped material, sustaining the action of the proton pump. An influx of Cl- ions and 
water accompanies the influx of protons and this causes swelling and the rupture of endosome, allowing 
entrapped material to escape (adapted from Chou et al. 2011). 
 
Another mechanism for endosomal escape is the destabilization of the endosomal membrane. 
Once inside the endosomes, cationic lipoplexes interact electrostatically with negatively charged 
lipids of the endosomal membrane. Consequently, anionic lipids of the endosomal membrane 
diffuse into the lipoplexes and form charge-neutralized ion pairs with the cationic lipids of the 
lipoplexes. As a result, the nucleic acids are moved from the lipoplexes, allowing the nucleic 
acids to be released into the cytoplasm(Liang & Lam 2012, Liu & Zhang 2011). 
 
Pore formation is another hypothesis proposed to explain the endosomal escape of peptide-
based nucleic acid delivery systems. This mechanism is based on the fact that some peptides 
have high affinity for the rim of the pore. Pore forming peptides induce bending of the 
membrane and contiguity of the bilayer leaflets, thus opening a pore in the membrane and 
facilitating release of endosomal contents (Medina-Kauwe et al. 2005, Varkouhi et al. 2011). 
 
The last hypothesis proposed to endosomal escape is the photochemical disruption of the 
endosomal membrane. Photochemical internalization (PCI) is a light-directed delivery method 
that utilizes photosensitizers to facilitate the transport of membrane impermeable 
macromolecules from endocytic vesicles into cytoplasm. Once confined in the endosome and 
exposed to light, these photosensitizers induce the formation of reactive oxygen species, mainly 
singlet oxygen, leading to the rupture of endosome membrane, whereas the contents of the 
organelles remain intact. As a result, entrapped material can be released into the cytosol (Liang 
& Lam 2012, Varkouhi et al. 2011). 
 
The last barrier that is critical for successful plasmid expression is the nuclear entry, because 
plasmids cannot be expressed unless they cross the nuclear envelope and enter the nucleus. 
The mechanisms of DNA nuclear translocation and whether the DNA stays associated with the 
delivery system are not yet well understood but this appears to depend on the type of delivery 
vehicle. However, there are three known pathways for DNA transport to the nucleus (Liu & 
Zhang 2011): 
Cl
- 
H2O 
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1. During the cell division stage, in which the nuclear membrane is temporarily broken 
down, allowing nuclear uptake of plasmid DNA. 
2. By passive transport through nuclear pores. The nuclear envelope is interrupted by 
large protein structures called nuclear pore complexes (NPC) which allow free diffusion 
of molecules less than 9 nm, or with MW less than 60 kDa or nucleic acids of up to 300 
bp. This route is not applicable to plasmids since gene delivery vectors are much larger 
than 9 nm. 
3. By active transport through nuclear pore complexes for particles less than 25 nm. This 
active transport is regulated by specific nuclear import and export systems such as 
nuclear localization signal (NLS) peptides (Al-Dosari & Gao 2009, Liu & Zhang 2011, 
Vaughan et al. 2006). 
 
After the plasmid enters the nucleus, a low level expression can occur and may be explained by 
the fact that, in most cases, the plasmid stays in the nucleus as an episomal DNA molecule 
without substantial chance to integrate into the host genome. During cell division these 
episomes do not replicate and will eventually be diluted away as the population of dividing cells 
grows (Al-Dosari & Gao 2009). 
 
1.3 NANOBIOTECHNOLOGY 
 
Nanotechnology is a multidisciplinary field that brings together diverse fields of research and 
development such as engineering, biology, physics and chemistry (Baptista 2009) .Formally, 
nanotechnology can be defined as the design, development and application of structures, 
devices and systems by controlling shape and size at the nanometer scale, i.e., at the level of 
atoms, molecules, and supramolecular structures. The nanometer scale is interesting in 
biological systems given the inherent nanoscale of functional components of living cells. So, it 
was inevitable that nanotechnology would be applied to biotechnology. Thus, the fusion 
between nanotechnology and biotechnology has created a new field of research – 
Nanobiotechnology (Eustis & el-Sayed 2006, Jain 2008, Khalel et al. 2010). 
 
Nanobiotechnology  can be considered a field that concerns the utilization of biological systems, 
such as cells, cellular components, nucleic acids, and proteins, to formulate functional 
nanostructures comprised of organic and inorganic materials, such as gold nanoparticles, 
magnetic nanoparticles, quantum dots, dendrimers, fullerenes, etc (Ladj et al. 2013, Nazir et al. 
2014). But it also concerns the development and application of instruments, originally designed 
to generate and manipulate nanostructured materials, to study fundamental biological 
processes and structures (Niemeyer & Mirkin 2004). Nanobiotechnology comprises all areas of 
physical and chemical sciences, biological sciences, health sciences and other interdisciplinary 
fields. In particular, bionanotechnology has had an increasing impact within the healthcare field. 
A number of clinical applications, such as disease diagnosis, target-specific drug delivery, gene 
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delivery and molecular imaging are being investigated at present (Fakruddin et al. 2012, Liang 
et al. 2012) 
  
Several approaches have been considered for the development of nanotheranostic techniques. 
However, nanoparticles (size range 1-100 nm) are one of the most common approaches, due 
their high surface-to-volume ratio, quantum size effect and electrodynamics interactions. 
Between these, gold nanoparticles are the most extensively studied nanomaterials and have led 
to the development of innumerous techniques and methods for molecular diagnostics, imaging, 
drug delivery, gene therapy, photothermal therapy and cell cycle regulation (Dreaden et al. 
2011, Liang et al. 2012). 
 
1.3.1 GOLD NANOPARTICLES 
 
Gold nanoparticles have been used since ancient times due to their optical properties, in 
particular for staining glass. Systematic investigations on gold nanoparticles go back to the days 
of Faraday, when he reported the formation of deep red solutions upon reduction of 
chloroaurate (AuCl4
-
) with white phosphorous. However their use in biological applications 
happened only in the last decade (Haiss et al. 2007, Sperling et al. 2008) 
 
Gold nanoparticles, also known as colloidal gold, are a suspension of sub-micrometer-sized 
gold metal particle in a fluid and can be obtained with diameters between 3 and 200 nm. AuNPs 
have gained increasing interest because they exhibit features which are fundamentally different 
from all other nanostructures. Their simple and fast preparation, controllable morphology and 
size dispersion and shapes, extraordinary optical and electronic properties, easy surface 
functionalization, high stability and biological compatibility, and the efficient conversion of light 
into heat, make them powerful agents within the anti-cancer nanotechnology filed of research 
(Huang et al. 2007, Sperling et al. 2008) 
 
Gold nanoparticles represent a versatile, potent, selective, and highly multi-functional anti-
cancer technology. Due their small size, gold nanoparticles can easily interact with 
biomolecules both at surface and inside cells, improving signals and providing target specificity 
for diagnostics and therapeutics (Conde et al. 2012b) 
 
1.3.1.1 Optical properties 
 
Once matter is exposed to light, several processes can occur and light can be absorbed, 
scattered at the same frequency as the incoming light (Rayleigh scattering), absorbed and re-
emitted (fluorescence) or enhanced, enhancing any spectroscopic signals from the molecules at 
the material surface (surface-enhanced Raman scattering). In the case of gold nanoparticles, all 
these processes are enhanced strongly owing to the unique interaction of light with the free 
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electrons on their surface (Huang et al. 2007). Gold nanoparticles have shown a range of 
biological and biomedical applications, due to their electrical, chemical and mainly to their 
strongly enhanced optical properties (Huang et al. 2007, Khan et al. 2013). The optical 
properties of gold nanoparticles are significant because absorption and emission can occur 
within the visible range of light (El-Sayed 2001). 
 
For biomolecular detection, an important feature of gold nanoparticles is the surface plasmon 
resonance (SPR). The SPR is the collective oscillation of the free electrons within the 
conduction band. The oscillation frequency is usually in the visible region giving rise to the 
strong SPR absorption. The SPR is very sensitive to the composition, size, shape, inter-particle 
distance and environment (dielectric properties) of the gold nanoparticles (Boisselier & Astruc 
2009, Conde et al. 2014a) .For gold nanospheres, 14 nm diameter nanoparticles, this 
resonance occurs in the visible spectral region at approximately 520 nm, which is the origin of 
the red color of these nanoparticles in solution (Eustis & el-Sayed 2006, Huang et al. 2007). The 
plasmon resonance frequency is changed when the average distance between gold 
nanoparticles is reduced (so that they form small aggregates), and as a consequence, the 
colloidal solution changes from red to dark blue and the SPR band changes to major 
wavelengths  (Sperling et al. 2008). 
 
1.3.2 GOLD NANOPARTICLES SYNTHESIS 
 
The first scientific report describing the production of colloidal gold nanoparticles came in 1857 
when Michael Faraday found that the ‘‘fine particles’’ formed from the aqueous reduction of gold 
chloride by phosphorus could be stabilized by the addition of carbon disulfide, resulting in a 
‘‘beautiful ruby fluid’ (Faraday 1857). Currently, the methods to obtain gold nanoparticles follow 
a similar strategy in which a gold salt is reduced in the presence of a reducing agent and a 
surface capping agent, the latter preventing aggregation of the particles by electrostatic 
repulsion (Dreaden et al. 2012). In 1951, Turkevich provided the first structural study of gold 
nanoparticles formed under varying synthetic conditions (Turkevich et al. 1954). Later, in 1973, 
Frens improved the Turkevich’s method, producing monodisperse spherical gold nanoparticles 
with different diameters (Frens 1973). 
 
The most common method for the synthesis of colloidal gold nanoparticles involve the chemical 
reduction of Au (III) to Au (0) by citrate in water. In the citrate reduction method, hydrogen 
tetrachloroaurate (HAuCl4) is reduced by sodium citrate. The particles are stabilized by citrate 
ions bound to the surface of the nanoparticles, resulting in negatively charged nanoparticles that 
repel each other by electrostatic repulsion. The sizes of the resulting gold nanoparticles are 
dependent of the citrate/Au ratio with larger ratios leading to smaller diameters (Dreaden et al. 
2011). 
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The second popular method using such sulfur coordination for gold nanoparticles stabilizations 
the Shiffrin–Brust biphasic synthesis using HAuCl4, a thiol, tetraoctylammonium bromide and 
NaBH4 in water–toluene yielding thiolate-AuNPs (Brust et al. 1994). Other methods to 
synthesize gold nanoparticles have also been reported. A multiplicity of other sulfur ligands 
such as xanthates, dithiocarbamates, disulfides, di- and trithiols, and resorcinarenes, 
polythioethers have been used to stabilize and synthesize AuNPs upon reaction with a Au (III)  
in the presence of a reductant. However, generally these ligands are not used for medical 
applications (Llevot & Astruc 2012). 
 
1.3.3 GOLD NANOPARTICLES FUNCIONALIZATION 
 
The gold nanoparticle surface represents one of the most stable and easily functionalized 
platforms for molecular conjugation. Functionalization of nanoparticles is necessary for their 
stability, functionality, specificity and biocompatibility. The main goal in functionalization is to 
maintain the properties of the gold nanoparticles and the bound molecules. The molecules 
should be stable and able to retain their features and gold nanoparticles should be able to retain 
their unique properties (Delong et al. 2010, Dreaden et al. 2011, 2012). 
 
In the design of biomedical gold nanoparticle conjugates, stability is an important feature 
because the physiological environments exhibit high ionic and serum concentrations which can 
disrupt and diminish the stabilizing capacity of many nanoparticle ligands. Thus, electrostatic 
repulsion alone is often insufficient to prevent particle aggregation. Poly(ethylene glycol) (PEG) 
is the most common surface ligand used to stabilize biomedical nanoparticles and can be 
attached to gold surface by a thiol linker. Pegylation not only increases stability and 
hydrophilicity, but also decreases immunogenic response from the nanoparticles, as well as 
their recognition by the reticuloendothelial system (RES) by minimizing adsorption of proteins 
and molecules which initiate phagocytic uptake (Dreaden et al. 2011, 2012). 
 
The gold nanoparticles surface can be functionalized with a variety of (bio) molecules such as 
DNA/RNA, oligonucleotides (siRNA, ssDNA), peptides, proteins, antibodies, polymers, drugs, 
cell surface receptors, and tumoral markers (Figure 1.4). If the (bio) molecule has a functional 
group which can bind to the gold surface, like thiols or specific peptide sequences, these can 
replace some of the original stabilizer molecules. Alternatively, (bio) molecules can be attached 
to the shell of stabilizer molecules around the gold nanoparticles by bioconjugate chemistry. 
The functional molecular linkers utilized for attachment of (bio) molecules to the gold surface 
generally include thiolates, dithiolates, amines, carboxylates, cyanides, isothiocyanates, 
phosphines, etc (Dreaden et al. 2011, Sperling et al. 2008, Tiwari et al. 2011).  
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Figure 1.4 – Schematic representation of a multifunctional nanoparticle. These innovative nanoparticles 
comprise nucleic acids, aptamers and anti-cancer drugs used for delivery to the target tissue. Tumoral 
markers, peptides, PEGs and antibodies can be used to improve nanocarrier circulation, effectiveness and 
selectivity. Reporter molecules attached to the particle surface can be employed as tracking and/or 
contrast agents (Conde et al. 2012b). 
 
The most common method to attach biomolecules by bioconjugate chemistry is the covalent 
linkage of amino groups on the biological molecules with carboxyl groups at the free ends of 
stabilizer molecules (e.g. thiolated PEG) by using 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide HCl-mediated reaction, as shown in Figure 1.5 (Sperling et al. 2008). 
 
 
Figure 1.5 – EDC coupling reaction scheme.  EDC is a zero-length crosslinking agent used to couple 
carboxyl groups to primary amines. In the presence of sulfo-NHS, EDC can be used to convert carboxyl 
groups to amine-reactive sulfo-NHS esters. The addition of sulfo-NHS stabilizes the amine-reactive 
intermediate by converting it to an amine-reactive Sulfo-NHS ester, thus increasing the efficiency of EDC-
mediated coupling reactions (Conde et al. 2014a). 
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The (bio) molecules can also be attached to gold nanoparticles by electrostatic adsorption of 
negatively charged (bio) molecules to positively charged nanoparticles or vice versa and by 
non-covalent binding, affinity-based receptor-ligand systems (Sperling & Parak 2010). 
 
1.3.4 GOLD NANOPARTICLES FOR DELIVERY APPLICATIONS 
 
Facing the problems inherent to current cancer treatments, nanotechnology has the potential to 
revolutionize cancer diagnosis and therapy. Thus, targeting of nanoparticles takes advantage of 
the inherent size of nanoparticles and the characteristic features of tumor biology, such as 
enhanced permeability and retention (EPR) effect, that allow nanoparticles to accumulate in the 
tumor, in conjunction with extracellular acidic pH, hypoxia, angiogenesis (development of a 
network of new blood vessels) and abnormal lymphatics. As a consequence of the EPR effect, 
the passive transport of macromolecules leads to their accumulation in tumors at considerably 
higher concentrations than in normal tissues, mostly 10-100 times higher within 1-2 days (Nazir 
et al. 2014). 
 
Nanotechnology had the main challenge to provide new cancer nanotherapies through the 
development of therapeutic nanocarriers that have the potential to provide effective therapies 
with minimal side effects and high specificity (Peer et al. 2007). 
 
Since nanocarriers encounter numerous barriers in route to their target, it is necessary to 
combine the rational design of nanocarriers with the fundamental understanding of tumour 
biology. Therefore, the developed nanocarriers should be capable of circulating in the blood 
stream undetected by the immune system, exhibit high differential uptake efficiency in the target 
cells over normal cells, be soluble or colloidal under aqueous conditions for increased 
effectiveness and have an extended circulating half-life (Peer et al. 2007).  
 
Nanocarriers can offer many advantages over free therapeutic agents. They can protect the 
therapeutic agent from premature degradation and prematurely interacting with the biological 
environment, can improve intracellular penetration and control the pharmacokinetic distribution. 
At last, nanocarriers take advantage of EPR (enhanced permeability and retention) effect which 
increase absorption of the agent into a selected tissue (Peer et al. 2007). 
 
1.3.4.1 CELLULAR UPTAKE AND TOXICITY OF GOLD NANOPARTICLES 
 
Gold nanoparticle size, colloidal stability and biocompatibility are the most exploited properties 
for delivery applications. The main goal of the incorporation of gold nanoparticles into the cells 
is to transfer molecules which are adsorbed on the surface of the gold nanoparticles. Targeting 
cancer cells is possible by conjugating gold nanoparticles with ligands specific to receptors 
 
15 
 
which are overexpressed on the surface of cancer cells but that are less present on healthy 
cells (Sperling et al. 2008). 
 
Understanding the mechanism of gold nanoparticle uptake by cells is important for intracellular 
drug and gene delivery. Most of the nanoparticle conjugates are capable of exhibiting some 
degree of intracellular incorporation. To internalize nanoparticles, cells utilize phagocytosis, 
macropinocytosis and receptor mediated endocytosis (RME) pathways including caveolae-
mediated, clathrin-mediated, and caveolae/clathrin independent endocytosis. For gold 
nanoparticles, most of the studies reported nanoparticles with dimensions of less than 100 nm 
and endocytosis has been proposed as the primary mechanism of cellular internalization. The 
size of nanoparticles was found to play a critical role in rate and extent of cellular uptake. In the 
work reported by Chithrani et al, it was found that 50 nm transferrin-coated gold nanoparticles 
were taken up by mammalian cells at higher rates and extents compared to smaller and larger 
sizes in the range of 10–100 nm (Chithrani et al. 2006). However the optimal particle size for 
intracellular uptake depends on the cell size, type, receptor density, metabolic activity, etc., as 
well as the specific targeting strategy employed. The characteristics of the nanoparticles also 
influence the cellular uptake, such as size, shape, surface, functionality/charge and aggregation 
state of nanoparticles (Alkilany & Murphy 2010, Dreaden et al. 2011, 2012). 
Once inside the cells, nanoparticles are stored in endosomal/lysosomal vesicular structures. To 
release nanoparticles from these structures to the cytosol, their surface can be coated with 
membrane-disruptive peptides or can be modified with peptides which allow for direct transfer 
across the cell membrane (Sperling et al. 2008). 
 
Regarding the cytotoxicity of gold nanoparticles, this field is somewhat controversial because 
toxicity may also depend on the cell lines used and the differences observed might perhaps be 
due to the different nature and properties of the various types of ligands. For example, cationic 
ligands can cause moderate toxicity due their ability to disrupt cell membranes.  Despite the fact 
that the gold nanoparticle’s core is considered inert and non-toxic, gold nanoparticles solutions 
‘‘as a whole’’ can induce toxicity. This toxicity could rise from any part other than the core itself, 
such as capping agents used in gold nanoparticle synthesis and stabilization, leftover chemicals 
from the synthesis, ligands, recognition molecules, etc (Boisselier & Astruc 2009, Dreaden et al. 
2012). 
 
According to many reports, gold nanoparticles have been found to be nontoxic. Using a 
leukemia cell line, Connor et al reported that gold nanospheres of different sizes (4, 12, and 18 
nm in diameter) and capping agents (citrate, cysteine, glucose, biotin, and 
cetyltrimethylammonium bromide) were found to be nontoxic based on MTT assays (Connor et 
al. 2005). Furthermore, Villiers et al. studied the toxicity of citrate-capped gold nanoparticles 
(spheres, 10 nm in diameter) on dendritic cells. They found that nanoparticles were not 
cytotoxic and did not change the phenotype of the studied cells (Villiers et al. 2010). In contrast 
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to these results, it was founded that gold nanoparticles less than 2 nm show evidence of 
chemical reactivity that does not occur at larger sizes (Turner et al. 2008). 
 
The variability of results could be due to the different used toxicity assays, cell lines, and 
nanoparticles chemical/physical properties. Thus, a systematic toxicity study must be carried out 
for each specific case under precise conditions, before imaging, diagnosis and therapeutic 
applications of gold nanoparticles.  Despite the importance of starting any toxicological 
screening using cell models, they do not provide results that can be extrapolated to conclude 
what the fate of these materials is in vivo. Thus, more in vivo studies are needed (Alkilany & 
Murphy 2010, Boisselier & Astruc 2009). 
 
1.4 OBJECTIVES 
 
The main goal of this project was to develop a gene delivery vector based on AuNPs to 
transfect a colorectal cancer cell line with EGFP expression vector and compare the efficiency 
with a commercial system (Lipofectamine). To achieve this goal various steps were needed: 
 
1) Synthesis of citrate capped AuNP and functionalization with PEG;  
2) AuNP@PEG functionalization with quaternary ammonium groups; 
3) Binding of AuNP@PEG@R4N+ with EGFP expression vector via electrostatic 
interactions; 
4) Characterization of AuNPs formulations; 
5) Transfection studies with AuNP@PEG@R4N+@pEGFP in HCT-116 cancer cell line 
and evaluation of transfection efficiency by PCR and EGFP expression by fluorescence 
microscopy and fluorescence spectroscopy. 
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2. MATERIALS AND METHODS 
 
2.1 NANOTECHNOLOGY 
 
2.1.1 GOLD NANOPARTICLES SYNTHESIS 
 
AuNPs were prepared by the reduction of tetrachloroaurate (HAuCl4) with sodium citrate 
described by Turkevich (Turkevich et al. 1954) and improved by Lee and Miesel (Lee & Meisel 
1982). 
 
Prior to the synthesis of gold nanoparticles, all the glass material was treated with aqua regia 
(3:1 HCl:HNO3) by immersion overnight. Then the material was washed with distilled water and 
mili-Q water (18.2 MΩ.cm
-1
 at 25ºC). 
 
In a 500 mL round bottom flask, 250 ml of 1 mM HAuCl4 (Sigma, MW 393.83 Da) was heated 
and stirred. When in reflux, 25 ml of 38 mM sodium citrate (Sigma, MW 294.1 Da) was rapidly 
added and the mixture was kept in reflux for 20 minutes with continuous stirring. The colloidal 
solution was left to cool to room temperature while keeping the continuous stirring and was then 
transferred to a 500 mL Erlenmeyer flask and stored in the dark at room temperature.  
The AuNPs were characterized by UV/Vis spectroscopy and their concentration was determined 
by the Lambert–Beer law assuming a calculated molar extinction coefficient for the plasmon 
resonance band maximum of 2.33x10
8
 M
−1
cm
−1 
(Baptista et al. 2005),Transmission Electron 
Microscopy and Dynamic Light Scattering.  
 
2.1.2 AuNPs FUNCTIONALIZATION WITH PEG CHAINS 
 
AuNPs were coated using a PEG functionalized with a thiol on one terminus and a carboxylated 
group on the other (SH-EG(8)-COOH, Iris.biotech, MW 458.57 Da). In order to achieve the 
concentration corresponding to 100% of PEG saturation of AuNP surface, a range of PEG 
concentrations were tested in a fixed amount of AuNPs. 
 
The synthesis of PEGylated AuNPs was carried out by mixing 10 nM of AuNPs with PEG with a 
range of concentrations of 0 - 0.1 mg/ml PEG and 0.028% SDS (Sigma, MW 288.38 Da). Then 
the mixtures were incubated overnight on a GFL 3016 shaker at room temperature. To remove 
the non-ligated PEG chains, each mixture was centrifuged (Sigma 3-16K, UK) 3 times for 30 
minutes at 14000 rpm, at 4ºC. The supernatants of the 3 washes were quantified by Ellman’s 
Assay to determine the number of PEG chains per AuNP. In this assay, the thiol group present 
in supernatants reacts with DTNB (5,5´-dithio-bis-(2-nitrobenzoic acid), (Sigma, MW 396.35 Da) 
under alkaline conditions, giving a yellow solution which absorbance can be read at 412 nm. 
 
 
18 
 
The Ellman’s assay was performed on a 96-well plate by mixing 200 μL of the supernatant of 
the 3 washes with 100 μL of phosphate buffer 0.5 M pH 7 – prepared by mixing 288.55 mM 
Na2HPO4 (Sigma) with 211.45 mM NaH2PO4 (Sigma) – and 7 μL of DTNB 2 mg/ml in phosphate 
buffer 0.5 M pH 7. After 10 minutes, the absorbance was measured at 412 nm. The number of 
bound PEG chains is given by the difference between the amount determined by Ellmans’s 
assay and the initial amount incubated with the AuNPs. 
 
The excess of PEG chains in the supernatants is quantified by interpolating a calibration curve 
set by replacing the supernatant with standard solutions of PEG (0.0002 – 0.5 mg/ml). 
 
In this work, the PEG concentration used to cover the AuNPs surface was 0.035 mg/mL. 
 
2.1.3 AuNPs FUNCTIONALIZATION WITH QUATERNARY AMMONIUM BY EDC/NHS 
COUPLING REACTION 
 
AuNP@PEG was functionalized with quaternary ammonium ((2-aminoethyl)trimethylammonium 
chloride hydrochloride, Sigma, MW 175.1 Da) by EDC (1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide)/NHS (N-hydroxysulfoxuccinimide) coupling reaction. 
 
For the functionalization, 21 nM AuNP@PEG was mixed with 1.25 mg/ml sulfo-NHS (Sigma, 
MW 217.13 Da), 10 mM MES pH 5.98 (Sigma, MW 195.24 Da) and 0.312 mg/ml EDC (Sigma, 
MW 191.7 Da) and incubated on a shaker for 30 min. Excess of reagents was removed by 
centrifugation for 30 minutes, at 14000 rpm and 4ºC.  After this, quaternary ammonium was 
added to the mixture in a range of concentrations of 0 – 10 mg/ml. The mixture was incubated 
overnight at room temperature while stirring. The unbound quaternary ammonium was removed 
by centrifugation 3 times for 30 min, at 14000 rpm and 4º C. 
 
In this work, the quaternary ammonium concentration used to functionalize AuNP@PEG was 
7.5 mg/ml (Conde et al. 2012a). 
 
2.1.4 FUNCTIONALIZATION OF AuNP@PEG@R4N+ WITH pEGFP VECTOR 
 
The complex formed between AuNP@PEG@R4N
+
 and the pEGFP vector (pVisionGFP-N 
vector 4.7 kb, Biovision – see section A1 in Appendix) is due to the positive charges of the 
quaternary ammonium groups and the negative charge of the pEGFP vector. 
 
The complex was prepared by mixing AuNP@PEG@R4N
+
 at a final concentration of 10 nM with 
increasing amounts of the plasmid in sterile mili-Q water from 0.2 to 50 ng/L (the pEGFP 
vector was always taken from a stock solution of 200 ng/l in order to keep the same volume of 
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EGFP vector).The solutions were incubated at room temperature for 1h. After this time, the 
unbound vector was removed by centrifugation 1 time for 20 min, at 14000 rpm and 4º C. 
 
The functionalization was assessed by UV/VIS spectroscopy, agarose gel electrophoresis and 
DLS measurements. 
 
For the transfections studies, the concentration of EGFP expression vector used was 11 ng/L. 
 
2.1.5 DYNAMIC LIGHT SCATTERING MEASUREMENTS 
 
To determine the hydrodynamic diameter of the naked and functionalized AuNPs, a set of DLS 
measurements was carried out. Thus, AuNPs were prepared in sterile mili-Q water at a final 
concentration of 2 nM and 1 ml of the sample was used for each measurement. Ten replicate 
measurements were obtained for each sample and each measurement lasts 30 seconds with a 
scattering angle of 90º at 25 ºC.  DLS analysis was performed in Horiba SZ-100 Nanoparticle 
Analyzer in Departamento de Química (FCT/UNL). 
 
2.1.6 TEM ANALYSIS 
 
TEM analysis was performed with a HITACHI H-8100 microscope operated at 200 kV in 
Instituto de Ciência e Engenharia de Materiais e Superfícies (ICEMS/IST), Portugal (contracted 
service). The samples were prepared by depositing 10 μL of the as-prepared colloidal 
suspensions in carbon copper grids, washing twice with 10 μL of milli-Q water, and air dried.  
 
Particle size and morphology were determined by analyzing the TEM pictures using the 
software image J. 
 
2.2 MOLECULAR BIOLOGY 
 
2.2.1 PREPARATION OF COMPETENT E.coli CELLS USING THE CACL2 METHOD 
 
E. coli cells (DH5), stored at -80 ºC, were inoculated on a LB agar plate and incubated 
overnight at 37ºC. A single colony was inoculated in 3 ml of LB medium and incubated overnight 
at 37ºC, while shaking at 180 rpm. In the next morning, the culture was diluted (1:200) in the 
same medium and the growth was followed by measuring the optical density at 600 nm until it 
reached an OD600nm=0.6. Cells were recovered by centrifugation at 7000 rpm for 5 min at 4ºC 
and then ressuspended in ½ of the initial volume in a 0.1 M CaCl2 solution (Sigma, MW 110.95 
Da) and stored on ice for 2 hours. Cells were recovered by centrifugation at 7000 rpm for 5 min 
at 4ºC and ressuspended in 1/15 of the initial volume in a 0.1M CaCl2 and 15% (w/v) glycerol 
solution (Pronalab).  
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Competent cells were aliquoted in 100-150 μl fractions and stored at -80ºC. 
 
2.2.2 E.coli TRANSFORMATION (based on the protocol by Ausubel et al., 1987) 
 
Five microliters (2000 ng) of pEGFP vector were added to 50 l of prepared E.coli competent 
cells and stored on ice for 50 min. The cells were then submitted to a heat shock at 42ºC for 90 
seconds and rapidly transferred to ice during 5 min. Then 900 l of LB medium were added and 
the cells were incubated for 1 hour at 37ºC, gently inverting the tubes every 10 min. Cells were 
recovered by centrifugation at 3000 rpm for 5 min and 850 L of the supernatant were removed. 
Cells were ressuspended in the remaining volume (105 L). After this, 100 μL of the 
transformed competent cells were cultured on LB agar plates with 30 μg/mL kanamycin (Life 
Technologies) and then incubated at 37ºC overnight. In the next day, an E.coli single colony of 
transformed competent cells was inoculated in 10 mL of LB medium supplemented with          
30 μg/mL kanamycin and incubated overnight at 37ºC, 180 rpm.  
 
Stock solutions of the transformed cells were prepared by adding 300 μL of glycerol to 700 μL of 
culture and stored at -80ºC. 
 
2.2.3 E. coli PLASMID EXTRACTION 
 
The plasmid extraction from E. coli was achieved using the alkaline lysis method. 
 
In the day before extraction, 100 L of an E.coli stock of transformed competent cells was 
inoculated in 10 mL of LB medium supplemented with 30 μg/mL kanamycin and incubated 
overnight at 37ºC, 180 rpm.  
 
A volume of 1.5 mL of the culture was transferred to an eppendorf. Cells were pelleted by 
centrifugation at 12 000 rpm for 2 min in 1.5 mL eppendorfs. The supernatant was discarded 
and the pellet was ressuspended in 100 μL of ice-cold lysis I
1
 solution and vortex to completely 
ressuspend cell pellet. After this, 200 μL of lysis II
1
 solution were added and mixed by inversion. 
After 2 min on ice, 150 μL of lysis III
1
 solution was added and vigorously mixed by vortex. After 
5 min on ice, the lysate was centrifuged at 12 000 rpm for 5 min. 400 μL of the supernatant was 
transferred to a sterile eppendorf and 2 volumes of ice-cold 100% ethanol were added. The 
plasmid DNA was left to precipitate at -20ºC for 2h and then centrifuged at 12 000 rpm for 5 
min. The supernatant was discarded and the pellet was washed with 1 ml of ice-cold 70% 
ethanol and left to air dry. The pellet was ressuspended in sterile mili-Q water. RNaseA 
(Fermentas) was added in a final concentration of 20 μg/mL and incubated for 2 hours at 37ºC. 
After this time, one extraction with 1 volume of phenol was performed, followed by one 
extraction with chloroform/isoamyl alcohol (24:1). Two volumes of absolute ethanol were added 
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to aqueous phase and the plasmid DNA was left to precipitate at- 20ºC for 2h like described 
above. Plasmid DNA was ressuspended in sterile mili-Q water and stored at 4 ºC. 
 
The plasmid extracted was quantified using the UV-Vis Spectrophotometer Nanodrop ND-1000 
(Nanodrop Technologies, USA). 
 
1 
Lysis solutions preparation is showing in appendix in section A2 
 
2.3 PCR FOR THE AMPLIFICATION OF THE GENE ENCODING EGFP AND FTO GENE 
 
The primers used for PCR to amplify the gene encoding the enhanced green fluorescence 
protein are shown in Table 2.1, as well as the expected product length determined using the 
tool “Primer-Blast” (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The complete reaction 
program is described in Table 2.2. 
 
The PCR was performed in a MyCycler Thermal Cycler (BioRad, Califórnia, EUA) and the 
reaction mixture was prepared in a 200 L microtube by adding 1x Taq Buffer (Fermentas, 
Canada), 1 mM dNTPs (Bioline, United Kingdom), 0.5 M EFGP primer forward (StabVida, 
Portugal), 0.5 M EFGP primer reverse (StabVida, Portugal), 2 U DreamTaq DNA polymerase 
(Fermentas, Canada), and sterile mili-Q water to bring the volume to 20 L. The amount of 
template used was 20 ng.  
 
Table 2.1 – Primers sequence used in PCR reaction to EGFP and FTO gene. 
Primers Sequence (5’- 3’) Product length (bp) 
EGFP Forward agcttcgaattctgcagt cg  
806 
EGFP Reverse ggctgattatgatctagagtc 
FTO Forward ttc aaa act ggc tct tga agt  
225 FTO Reverse cag tca gaa atg gag tgg gag 
 
Table 2.2 – Reaction Program to amplify the gene encoding EGFP. 
 Temperature (ºC) Time Cycles 
Initial Denaturation 95 1 min 1 
Denaturation 95 30s  
30 
 
Annealing 57.5 30s 
Extension 72 1 min 
Final Extension 72 10 min 1 
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FTO gene (housekeeping gene) was used as internal control of transfection studies. PCR for 
FTO gene was performed by adding in a 200 L microtube 1.5 x Hot Taq Buffer (StabVida, 
Portugal), 2.5 mM MgCl2 (StabVida, Portugal), 0.2 mM dNTPs (Fermentas, Canada), 0.4 M 
FTO primer forward (StabVida, Portugal), 0.4 M FTO primer reverse (StabVida, Portugal), 2 U 
Hot Taq DNA polymerase (StabVida, Portugal) and sterile mili Q water to bring the volume to 
25 L. The amount of template used was 20 ng. 
 
Table 2.3 – Reaction Program to amplify FTO gene. 
 Temperature (ºC) Time Cycles 
Initial Denaturation 95 ºC 15 min 1 
Denaturation 94 ºC 1 min  
35 Annealing 60 ºC 30 s 
Extension 70 ºC 30 s 
Final Extension 70 ºC 6 min 1 
 
PCR products were analyzed by 1% agarose gel electrophoresis (1x TAE, 60 V, and 1h 30).  
 
2.4 CELL CULTURE MANIPULATION 
 
HCT-116 cells (from colorectal carcinoma) were grown in Dulbecco's modified Eagle's medium 
with Glutamax (DMEM, Invitrogen) with 10% heat inactivated fetal bovine serum (FBS, 
Invitrogen), 100 U/mL penicillin and 100 μg/mL streptomycin (Invitrogen). Cells were maintained 
in a CO2 incubator with 5% (v/v) CO2, at 37ºC in 99 % humidified atmosphere in 75 cm
2
 culture 
flask (VWR). 
 
Cell cultures were transferred to a new cell culture flask upon reaching a confluence of about 
80%, which was verified by inverted optical microscopy (Nikon TMS). To this end, all medium 
was aspirated, cells were washed once with 1x PBS pH 7.4, 2 ml trypsin 1x (Invitrogen) was 
added and the flask was placed in the CO2 incubator for 5 min. Once all cells were detached 
from the flask, 8 mL of fresh serum-containing medium was added to neutralize the trypsin 
action. Fifteen mL of growth medium was placed in a new 75 cm
2 
culture flask and 500 L of 
cells were added to the flask. Cells were grown for 18 - 24h in a CO2 incubator prior to any 
experiment was performed. 
 
2.4.1 DETERMINATION OF CELL CONCENTRATION 
 
For the transfection studies, a certain number of cells are needed. To perform the cell count, 20 
L of cells were mixed with 80 L of Trypan Blue 0.4% (m/v) (Sigma). Ten L of this mixture 
was then added to a Neubauer chamber (Hirschmann, Germany) and the viable cells were 
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counted by visualization on an inverted microscope. Trypan blue is a dye that is capable of 
trespassing the plasma membrane of non-viable cells, since these cells have a more permeable 
cell membrane. Thus, cells that are viable do not have any coloration whereas non-viable cells 
are blue. The number of cells per mL is given by the equation (1):
 
 
𝑁𝑜.  𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠
𝑚𝐿
=  
𝑛𝑜.𝑜𝑓 𝑣𝑖𝑎𝑏𝑙𝑒 𝑐𝑒𝑙𝑙𝑠 𝑜𝑓𝑞𝑢𝑎𝑑𝑟𝑎𝑛𝑡𝑠 1 𝑡𝑜 4
4
𝑥104  x dilution factor          (1) 
 
2.5 TRANSFECTIONS STUDIES 
 
2.5.1 EGFP VECTOR TRANSFECTION 
 
In order to study the transfection efficiency of the gold nanoparticles conjugates, transfection 
experiments were performed in HCT-116 cells.  
 
HCT-116 cells were seeded at a density of 1 x 10
5
cells/well in 24-well plate in 500 L of DMEM, 
maintained at 37º C in 5% CO2 and grown for 24 h prior to transfection. On the day of 
transfection, cells were approximately 80% of confluence. Thus, the medium was removed, cells 
were washed 1 time with 1x PBS pH 7.4 and 400 L of DMEM was added to each well. The 
complex AuNP@PEG@R4N
+
@pEGFP functionalized with 11 ng/L was freshly prepared and 
100 L of the complex were added to each well, containing  400 L of DMEM, in order to get a 
final amount of pEGFP vector of 1 g per well. 
 
As a positive control Lipofectamine 2000 (Invitrogen) was used as the transfection reagent, 
according to manufacturer’s protocol. The lipoplex is formed according to a ratio DNA 
(µg):Lipofectamine 2000 (µl) of 1:2. 
 
For 24-well plate, 1 μg (5 μL of a stock solution of 200 ng/μL) of EGFP vector was diluted in 
45 μL of Opti-MEM reduced serum medium and 2 μL of Lipofectamine 2000 was diluted in      
48 μL of the same medium. After 5 min of incubation, EGFP vector solution was added to 
Lipofectamine 2000 solution, mixed gently, and incubated for another 20 min at room 
temperature to allow lipoplex formation. After this time, 400 L of DMEM antibiotic free was 
added to the complex and then added to the cell-containing wells. 
 
The transfection efficiency was evaluated by fluorescence spectroscopy, fluorescence 
microscopy and PCR at different incubation times from 3 to 48h.  
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2.5.2 FLUORESCENCE MICROSCOPY 
 
HCT-116 cells were seeded at a concentration of 1 x 10
5
 cells/well in 24-well plate over glass 
coverslips in 500 L of DMEM (Invitrogen) with 10% heat-inactivated fetal bovine serum 
(Invitrogen) and maintained at 37 º C in 5% CO2 (grown for 24 h prior to transfection). The 
transfection was performed as described in section 2.5.1. EGFP expression was assessed at 
different incubation times from 3 to 24h. 
 
After each incubation time, cells were washed 1 time with 1x PBS pH 7.4 and fixed with 4% 
paraformaldehyde in PBS for 15 min. The glass coverslips was washed 3 times with 1x PBS pH 
7.4 and mounted in 10 L ProLong Gold Antifade Reagent with DAPI (Invitrogen) to allow for 
nuclear staining. The glass slides were observed in an Axioplan 2 microscope (Zeiss, 
Germany). 
 
2.5.3 EGFP EXPRESSION EVALUATION BY FLUORESCENCE SPECTROSCOPY 
 
EGFP expression was evaluated by fluorescence spectroscopy at different incubation times 
from 3 to 48h. Thus, all medium was removed; cells were washed with 1x PBS (to remove the 
cell culture medium) and 100 L of sterile mili-Q water was added to each well. The plate was 
placed on a shaker for 30 min in order to lyse the cells by osmotic shock. After vigorous 
shaking, the lysate was transferred to 1.5 mL tubes and briefly sonicated and centrifuged at     
13 000 g for 25 min at 4ºC. 
 
EGFP fluorescence was determined by placing 70 L of the lysate in a quartz cuvette, and 
using a Varian Cary Eclipse spectrofluorimeter, in a range 490-650 nm, after excitation at 480 
nm. 
 
2.5.4 EVALUATION OF AuNP UPTAKE BY CELLS 
 
In order to confirm the uptake of the nanoconjugate AuNP@PEG@R4N
+
@pEGFP by cells and 
confirm the presence of the plasmid inside the cells, a PCR was performed to amplify the gene 
encoding EGFP.  
 
This assay was performed incubating the nanoconjugate and Lipofectamine 2000, as described 
in section 2.5.1, at different time points of 3h, 6h, 12h and 24h. After incubation time, the 
medium was removed and the wells were washed three times with 1x PBS pH 7. Cells were 
detached adding 100 L trypsin 1x and the plate was placed in CO2 incubator for 5 min. Once 
all of the cells have detached, 400 L of DMED were added to neutralize the trypsin action and 
the total 500 L were transferred to an eppendorf tube for DNA extraction. 
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Total DNA was extracted from cells transfected with Lipofectamine 2000 (positive control) and 
nanoconjugates, and non-transfected cells (negative control) using QIAamp DNA Mini Kit 
(Qiagen) and quantified using the UV-vis Spectrophotometer Nanodrop ND-1000. The DNA 
extracted was used to perform the PCR using the primers presented in Table 2.1 and the 
reaction program described in Table 2.2, presented in section 2.3. As internal control, FTO gene 
was used and the primers, as well as the reaction program, are described in Tables 2.1 and 2.3 
in section 2.3. 
 
2.6 MTS ASSAY 
 
Standard MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay was performed to determine the cytotoxicity of the functionalized AuNP 
complexes compared with the Lipofectamine 2000. When MTS is exposed to PMS, it is 
converted into formazan by viable cells which are brown. Thus, this colorimetric method is often 
used to determine the number of viable cells 
 
HCT-116 cells were transfected in 96-well plates as described in section 2.4.1 but using a cell 
density of 1 x 10
4
cells/well and incubated for 48h. The viability was assessed using Kit CellTiter 
96 AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, EUA) according to 
the manufacturer’s protocol. After the incubation time, the culture medium was removed from 
each well and replaced by 100 L of MTS solution in a ratio of 100:20:1 of DMEM, MTS and 
PMS, respectively. The plate was incubated for 30 min in a CO2 incubator with 5 % (v/v) CO2, at 
37ºC. Then the absorbance at 490 nm was measured in a Microplate reader Infinite M200 
(Tecan, Smitzerland) and the cell viability was given by the equation (2):  
 
Cell viability (%) = 
𝐴𝑏𝑠 490 𝑛𝑚 (𝑠𝑎𝑚𝑝𝑙𝑒)
𝐴𝑏𝑠 490 𝑛𝑚 (𝑐𝑜𝑛𝑡𝑟𝑜𝑙)
 x 100          (2) 
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3. RESULTS AND DISCUSSION 
 
3.1 GOLD NANOPARTICLES SYNTHESIS AND CHARACTERIZATION 
 
The synthesis of gold nanoparticles was achieve by reduction of sodium tetrachloroaurate (III) 
hydrate with sodium citrate dehydrate, yielding AuNPs with an average diameter of 14 nm. 
AuNPs characterization by UV-vis spectroscopy revealed a single absorbance band in 521 nm 
due to the localized surface plasmon resonance (LSPR). The spectrum indicates relatively 
monodisperse spherical particles due the symmetric absorption peak at 521 nm (see Figure 
3.1b). The concentration of AuNPs was determined via the Lambert-Beer equation, assuming 
an extinction coefficient of 2.33 x 10
8
 M
-1
 cm
-1 
for the plasmon resonance band (Baptista et al. 
2005), resulting in a concentration of about 14  nM. 
 
TEM analysis provides direct visualization of morphology and size distribution of synthesized 
AuNPs. TEM image shown in Figure 3.1a confirms the data of the UV-vis. The diameter 
determined from TEM image using the software Image J was 14.28 nm ( 0.2), which was in 
agreement with the hydrodynamic diameter determined by DLS, 14.14 nm ( 0.4). 
 
 
Figure 3.1 - Characterization of the synthesized AuNPs: (a) Transmission electron microscopy (TEM) 
showing monodispersed spherical AuNPs (scale bar 20 nm); (b) UV-vis spectrum of the synthesized gold 
nanoparticles revealing a SPR band at 521 nm. 
 
3.2 GOLD NANOPARTICLES FUNCIONALIZATION 
 
3.2.1 POLY (ETHYLENE GLYCOL) (PEG) 
 
To increase the stability, biocompatibility and allow chemical functionality with quaternary 
ammonium groups, citrate capped AuNPs were functionalized with a thiolated poly (ethylene 
glycol) (PEG) (HS-PEG(8)-COOH). This polymer is a water-absorbing molecule that has the 
ability to attract water molecules, creating a shield around the AuNPs, which allows them to 
a b 
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travel through the body’s blood vessels and which increases the stability and biocompatibility of 
the nanocarrier. 
 
The PEGylation of the AuNPs occurs through the complete exchange of the citrate molecules 
surrounding the AuNPs surface with PEG chains, creating an Au-S quasi-covalent bond. The 
carboxylated group provides the anchoring moieties for the covalent binding of amine-
containing molecules through carbodiimide chemistry. 
 
In order to produce AuNPs capped with a 100% saturation layer of PEG, various concentrations 
of PEG were added to the synthesized AuNPs from 0 – 0.1 mg/ml. The excess of PEG was 
removed by centrifugation and the supernatants resulting from the three washes were quantified 
by the Ellmans’s assay, by interpolating the calibration curve shown in Figure 3.2a. The number 
of bound chains to the AuNPs surface was given by the difference between the amount 
determined by this assay and the initial amount of chains in the incubation mixture. It was 
determined that the maximum coverage per AuNP was 0.035 mg/ml, because it was the 
concentration where PEG molecules were detected in the supernatant. Thus, gold nanoparticles 
were functionalized with 0.035 mg/mL of SH-PEG(8)-COOH, corresponding to 100% of PEG 
saturation of AuNP surface (4300  114 chains/AuNP). 
 
Figure 3.2 b shows the excess of PEG in the first supernatant as a function of the initial 
concentration in an incubation mixture. As the initial PEG concentration increases, the excess of 
free PEG increases. There was a point at which the AuNP becomes saturated with a PEG layer 
and was not able to uptake more PEG chains, that is 0.035 mg/ml. 
 
 
Figure 3.2 – (a) Standard calibration curve for PEG chains, whose concentration can be calculated via the 
following equation Abs412nm = 7067.3 x [PEG] (M) + 0.0279. (b) Variation of the excess of PEG thiolated 
chains as a function of the initial concentration in the incubation with 10 nM AuNPs. The vertical line 
indicates the 100% saturation, i.e. the PEG concentration above which no more PEG can be bound to the 
AuNP surface. 
 
Once determined the ideal concentration to fully cover AuNP surface as well PEG chain/AuNP, 
UV-vis and DLS analysis were performed to characterize the functionalized AuNPs. UV-vis 
y = 7067.3x + 0.0279 
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spectrum exhibited a shift on the SPR band from 521 to 524 nm, a 3 nm shift for PEG binding, 
meaning an increase in the diameter (see Figure 3.3). To confirm the functionalization, the 
AuNPs were analyzed by DLS, which reveals an increase in hydrodynamic diameter from 14.14 
nm to 35.2 nm ( 1.2). The length of a PEG chain is 3.25 nm (www.iris-biotech.de), so it would 
be expected an increase of the diameter of 6.5 nm, instead of 21.06 nm. The difference 
between expected values and experimental values can be explained by the formation of 
multiple layers of PEG on the AuNPs surface. Furthermore, PEG is a flexible polymer that can 
change the Brownian motion of the AuNPs, thus introducing a frictional drag and reducing the 
diffusion of the AuNP. This results in an increase of the hydrodynamic diameter of the AuNP. 
 
Figure 3.3 – UV-vis spectra of synthesized AuNPs and coated with PEG chains, revealing a shift from 521 
to 524 nm, a 3 nm shift of the SPR band for PEG binding. 
 
3.2.2 QUATERNARY AMMONIUM 
 
Gold nanoparticles functionalization with (2-Aminoethyl)trimethylammonium chloride 
hydrochloride was carried out via an EDC/NHS reaction, which created a bond between the 
carboxylated  PEG spacer and the amine group of (2-aminoethyl)trimethylammonium 
hydrochloride.  
 
It has been showed that quaternary ammonium groups are capable to bind plasmid DNA 
through electrostatic interactions and that it can protect DNA from enzymatic digestion (Han et 
al. 2006, McIntosh et al. 2001). These cationic groups have also been described as having a 
possible proton sponge effect played by the carboxylic group and quaternary ammonium 
groups, which could be responsible for endosome rupture and release of the trapped materials 
into the cytoplasm (Yezhelyev et al. 2008). 
 
To determine the optimal of ammonium groups to get full coverage of the gold nanoparticle 
surface, a range of concentrations from 0 – 10 mg/ml (2-Aminoethyl)trimethylammonium 
chloride hydrochloride were mixed with 21 nM of AuNPs. Since it was not possible to quantify 
the amine groups in the supernatants, the functionalization was evaluated by UV-vis 
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spectroscopy (see Figure 3.4) and through the work developed by Conde et al., where an ionic 
approach was employed to bind siRNA to 14 nm AuNP coated with PEG and the same 
quaternary ammonium compound used in this work (Conde et al. 2012a). 
 
 
Figure 3.4 – UV-vis spectra of AuNP@PEG coated with increase amount of quaternary ammonium. When 
the R4N
+
 group is not added, SPR absorption band is located at 523 nm, while in the presence of 
quaternary ammonium a shift to 526 nm is observed. 
 
The functionalization was evaluated through UV-vis spectroscopy, since the SPR band is 
dependent on the size, shape, aggregation state and medium polarity. As shown in Figure 3.4, 
a shift in the surface plasmon resonance band from 523 to 526 nm was observed in samples 
where increasing amounts of quaternary ammonium were added (0 – 10 mg/ml). This shift to 
526 nm may be associated to an increase in the diameter and a change in the chemical 
environment surrounding the AuNP@PEG surface. Since the shift was the same for any 
concentration, it appears that the environment surrounding the AuNP@PEG surface was the 
same, and above 1 mg/ml no more quaternary ammonium can be bound  to the AuNP@PEG 
surface. 
 
Since these results were not conclusive, the quaternary ammonium concentration used to cover 
the AuNP@PEG surface was 7.5 mg/ml and the nanoconjugate was characterized by UV-vis 
spectroscopy and DLS. This value was extrapolated from the work developed by Conde et al. in 
which a similar formulation was developed (Conde et al. 2012a). 
 
As shown in Figure 3.5, the double functionalization of the AuNPs (PEG plus quaternary 
ammonium molecules) results in a shift of the SPR band towards larger wavelengths, which 
may be associated to changes in the dielectric environment surrounding AuNPs. When 
functionalized with 7.5 mg/ml of quaternary ammonium, the spectrum of AuNP@PEG exhibits a 
2 nm shift from 524 to 526 nm, meaning an increase in the diameter. DLS analysis reveals an 
increase in hydrodynamic diameter from 35.2 to 43.9 nm (1). A large increase on the 
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hydrodynamic diameter was not expected since quaternary ammonium groups show a small 
molecular footprint (Yezhelyev et al. 2008). 
 
Figure 3.5 – UV-vis spectra of synthesized AuNPs, AuNP@PEG and AuNP@PEG coated with 7.5 mg/ml 
of quaternary ammonium, revealing a shift from 524 (AuNP@PEG) to 526 nm, a 2 nm shift of the SPR 
band for quaternary ammonium binding. 
 
3.2.3 EGFP PLASMID BINDING TO AuNP@PEG@R4N+ 
 
Due the strong negative charge of nucleic acids, the nanoconjugate AuNP@PEG@R4N
+
 has 
the ability to bind plasmid DNA thought electrostatic interaction, since the surface of the AuNP-
based formulation is positively charged. An analogous complex was described by Sandhu et al. 
who created a delivery vehicle to bind plasmid DNA using quaternary ammonium–functionalized 
AuNPs (Sandhu et al. 2002) with a gold core of 2 nm and a total diameter of 6 nm. In these 
AuNP@DNA complexes, the DNA is bent around the AuNPs into a “spaghetti and meatballs” 
motif, protecting the DNA from degradation. 
 
To study the interaction between nanoconjugate and plasmid DNA, increase amounts of pDNA 
were added to a fixed concentration of AuNP@PEG@R4N
+
 (10 nM). After 1 hour of incubation 
at room temperature, the samples were centrifuge one time for 25 min at 14000 rpm at 4ºC to 
eliminate the unbound pDNA. This binding was studied by UV-vis spectroscopy using the 
surface plasmon resonance of the gold nanoparticles as indicator of functionalization and the 
absorbance at 260 nm. Thus, spectra of these samples were taken in a range from 200 – 
750 nm. 
 
The absorbance spectra obtained from the assay described above are shown on Figure 3.6. 
Regarding to the SPR band, it was observed that the greater the concentration of pDNA added, 
the greater the red-shift (see Table 3.1), which may be indicative that there was always plasmid 
bound to AuNPs.  
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Table 3.1 – SPR band of the AuNP@PEG@R4N
+
@pEGFP, which increases with increasing concentration 
of pEGFP. 
[pEGFP] 0.2 ng/L 0.5 ng/L 1 ng/L 2 ng/L 11 ng/L 50 ng/L 
SPR (nm) 526 528 529 531 533 ~ 650 
 
Regarding the absorbance around 260 nm, corresponding to the absorption maximum of 
nucleic acids, an opposite behaviour was observed and there was a trend in which the greater 
the concentration of pDNA, the lower the absorbance at 260 nm. This may be due to 
conformational changes to the pDNA, such as increased condensation, forming of aggregates 
and/or strand stacking, leading to a hypochromic effect (Ozluer & Kara 2014). 
 
Concerning the sample related to 50 ng/L pDNA, it was observed a change in the color or the 
AuNPs from red to purple-blue. This color change caused a shift to a wavelength of 650 nm, 
which is indicative of AuNPs aggregation.  
 
Figure 3.6 – UV-vis spectra of AuNP@PEG@R4N
+
@pEGFP were taken 1h after addition of the plasmid 
and centrifuge one time. A shift on SPR band to larger wavelengths was observed as the concentration of 
plasmid increased.  
 
Figure 3.7, reveals the importance of including R4N
+
 groups to ensure electrostatic interactions 
between the positively charged AuNPs and the negatively charged pDNA. There was no shift 
observed in surface plasmon resonance band when AuNP@PEG was incubated with pEGFP, 
remaining the peak at 523 nm. So, it was possible to conclude that the binding of plasmid to 
gold nanoparticles surface was exclusive due to quaternary ammonium groups. 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
200 300 400 500 600 700
A
b
so
rb
an
ce
 
Wavelength (nm) 
AuNP@PEG@R4N+@pEGFP 0.2 ng/uL
AuNP@PEG@R4N+@pEGFP 0.5 ng/uL
AuNP@PEG@R4N+@pEGFP 1 ng/uL
AuNP@PEG@R4N+@pEGFP 2 ng/uL
AuNP@PEG@R4N+@pEGFP 11 ng/uL
AuNP@PEG@R4N+@pEGFP 50 ng/uL
 
33 
 
 
Figure 3.7 – UV-Vis spectra of AuNP@PEG@DNA were taken 1h after addition of the pDNA and 
centrifuge one time. No binding of the pDNA was observed, once no shift on the SPR band was observed 
and the absorbance at 260 nm suffered no change. 
 
The functionalization was also assessed by agarose gel electrophoresis and the hydrodynamic 
diameter of the complex was determined by DLS analysis. 
 
Gel electrophoresis was carried out initially to test the association of AuNPs with pEGFP. Thus, 
the samples corresponding to the spectra shown in Figures 3.6 and 3.7, as well as their 
supernatants were submitted to an electrophoretic analysis in agarose gel, as shown in 
Figure 3.8. 
 
It is possible to observe a complete inhibition of electrophoretic mobility of the plasmid when 
pDNA was complexed to the AuNP@PEG@R4N
+
 in a range of concentrations of 0.2 – 
11 ng/L; no electrophoretic mobility of pDNA for samples and their respective supernatants in 
lane 2 – 6 and lane 8 – 12, respectively. This suggests that the complex was completely 
neutralized and the entire plasmid was bound or the complex was too large to migrate into the 
gel. An electrophoretic mobility of pDNA toward the positive electrode was observed in the 
supernatant of the sample where AuNP@PEG@R4N
+ 
was incubated with 50 ng/L of pDNA, 
(lane 13), suggesting that an excess of pDNA was present and did not bind to the AuNPs. 
 
To confirm that pDNA was incapable to bind to AuNPs in the lack of quaternary ammonium 
groups, these samples and theirs supernatant were also submitted to an electrophoretic 
analysis in agarose gel (see Figure 3.8). In the case of the samples (lane 14 – 19), plasmid was 
not observed indicating that this did not bind to the AuNP@PEG. As can be seen in lane 22 – 
25, the plasmid did not bind to the AuNPs and consequently came out in supernatants. At lower 
concentrations (0.2 and 0.5 ng/L, lane 20 and 21, respectively), electrophoretic mobility of the 
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pDNA is almost not visible probably because these concentrations are very close to the 
detection limit of the technique (0.1 ng DNA to GelRed stain (www.biotium.com)). Once again, it 
can be concluded that the binding of plasmid to AuNPs is due to the presence of quaternary 
ammonium groups. 
 
 
 
Figure 3.8 – Agarose gel electrophoresis (1%, TAE 1x, 80 V for 60 min) of 
AuNP@PEG@R
4
N
+
@pEGFPcomplexes prepared at the concentrations of pEGFP (0.2 – 50 ng/l) given 
on top with a fixed amount of AuNPs (10 nM): lane 1 – plasmid DNA only; lane 2 - 7 – 
AuNP@PEG@R
4
N
+
@pEGFP 0.2 – 50 ng/l; lane 8 - 13 – supernatants from the samples 
AuNP@PEG@R
4
N
+
@pEGFP 0.2 – 50 ng/l; lane 14 - 19 – AuNP@PEG@ pEGFP 0.2 – 50 ng/l; lane 20 
- 25 – supernatants from the samples AuNP@PEG@pEGFP 0.2 – 50 ng/l.  
 
The concentration of the plasmid bound on the AuNPs surface intended to transfect cells (1 g) 
was 11 ng/L. This amount was selected for transfection because it was the same amount 
transfected with Lipofectamine 2000 and would allow for direct comparison of efficiency. DLS 
analysis was performed with the AuNP complex functionalized with 11 ng/L in order to obtain 
the hydrodynamic diameter. 
 
DLS analysis reveals a hydrodynamic diameter of 113.5 nm ( 0.8), an increase of 69.6 nm in 
relation to AuNP@PEG@R4N
+
. The diameter of the plasmid is dependent of the size, 
conformation, charge, temperature and solvent. Thus, it is difficult to predict the increase in the 
diameter of AuNPs. Furthermore, plasmids change conformation to bind to the AuNPs surface, 
which adds to size variations (Sandhu et al. 2002). 
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Despite the size of the nanoconjugates, internalization by cells was still expected as reported by 
Gosh et al. using amino acid-coated nanoparticles with a diameter around 100 nm, which were 
efficiently internalized with -gal plasmid in mammalian cells (Ghosh et al. 2008). 
 
Regarding the SPR band of the AuNP@PEG@R4N
+
@pEGFP functionalized with 11 ng/L of 
pEGFP, a 7 nm shift occurred from 526 to 533 nm, when the plasmid was bound to AuNPs 
surface (see Figure 3.9). This shift is associated to the increases of the AuNPs diameter and by 
charge alterations on the surface of the AuNPs. While the functionalization with quaternary 
ammonium groups turn the surface more positive, binding of the plasmid makes them slightly 
less positive. Plasmid binding led to a shift in SPR band once this is dependent of factors such 
as size, shape, and charge surface. 
 
 
Figure 3.9 – UV-vis spectra of synthesized AuNPs and functionalized with PEG, quaternary ammoniums 
and pEGFP. The SPR band exhibited a shift to major wavelengths while the different groups bound to 
AuNPs surface. 
 
Once no plasmid was detected in the supernatant when plasmid was attached on AuNPs, it was 
considered that all plasmid was bound on AuNPs surface. Thus, for the transfection studies, no 
more centrifugations were done so as to avoid unnecessary precipitation of some AuNPs in the 
walls of the tubes, which alters the concentration of the AuNPs and consequently the amount 
required for transfection (the spectrum of the complex shown in Figure 3.9 was taken without 
further centrifugation). 
 
With the results presented until now, it was possible to conclude that the AuNP-based 
formulation developed would be capable to be used as a vehicle to transport the plasmid inside 
the cells in order to express EGFP protein. 
 
 
ng/L 
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3.3 TRANSFECTION STUDIES 
 
To assess the potential of the AuNP@PEG@R4N
+
@pEGFP as gene delivery, colorectal cancer 
(HCT-116) cells were transfected with an EGFP expression vector complexed on the AuNP-
based formulation. These cells were chosen due to the relevance of colorectal carcinoma (see 
section 1.1) and also due to the extensive expertise within the Nanomedicine@FCT group in 
transfecting EGFP plasmid using Lipofectamine 2000 (Conde et al. 2014b). The ability of the 
nanoconjugates to deliver the EGFP vector was compared to the standard pDNA transfection 
using Lipofectamine 2000. 
 
To make this comparison possible, the amount of EGFP expression vector used in transfection 
assays was 1 g in both Lipofectamine 2000 (according to manufacturer’s protocol) and the 
nanoconjugate. In the case of the nanoconjugate used in transfection assay, this was 
functionalized using a concentration of 11 ng/l because this was the concentration in which the 
amount desired to transfect (1 g) was complexed to the AuNPs. 
 
Transfection efficiency is the most important factor to assess the quality of gene delivery vectors 
and measuring the intracellular expression of EGFP is an excellent way to investigate the 
quality of the delivery vector developed. Thus, EGFP expression was assessed by fluorescence 
microscopy and fluorescence spectroscopy. 
 
3.3.1 EGFP EXPRESSION EVALUATION BY FLUORESCENCE SPECTROSCOPY AND 
FLUORESCENCE MICROSCOPY 
 
Previous studies, reported by Vaughan & Dean, where a GFP expressing plasmid was 
microinjected into the cytoplasm of cultured cells, showed a significant level of expression after 
4 hours (Vaughan & Dean 2006). Thus, EGFP expression was evaluated at different 
incubations times from 3 – 48 h, in order to follow the increase of the expression. 
 
Images of fluorescence microscopy were acquired using two different filters. To visualize DAPI 
stain, which allows imaging of the cell nucleus (DAPI emission 461 nm), the blue filter was used 
(range 430 – 465 nm)  and to assess EGFP expression, a green filter was used (range 500 – 
550 nm). Figure 3.10a shows these images of the non transfected cells (control) and cells 
transfected with Lipofectamine 2000 and AuNP@PEG@R
4
N
+
@pEGFP that were acquired after 
3h and 6h incubation. The relative EGFP expression 3h and 6h post transfection is also 
represented in Figure 3.10b and was acquired measuring the fluorescence intensity of cell 
lysates, after excitation at 480 nm and emission at 510 nm. 
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Figure 3.10 – (a) Images obtained by fluorescence microscopy (scale bar, 50 m) of HCT-116 cells 
transfected with EGFP expression vector, using Lipofectamine 2000 and AuNP@PEG@R
4
N
+
@pEGFP, 
after 3h and 6h incubation. HCT-116 cells transfected using Lipofectamine 2000 shows a low level of 
EGFP expression, while with the AuNP@PEG@R
4
N
+
@pEGFP no expression was achieved; (b) Relative 
expression of EGFP was assessed by fluorescence spectroscopy, 3h and 6h after transfection HCT-116 
cells transfected with 1 g of the EGFP expression vector, using Lipofectamine 2000 and 
AuNP@PEG@R
4
N
+
@pEGFP. Not transfected cells and withAuNP@PEG@R
4
N
+ 
were used as control. 
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Regarding the cells transfected with Lipofectamine 2000, the acquired images show some 
expression of EGFP as early as 3h and 6h post-transfection (see Figure 3.10a) , although a low 
level. These results are in agreement with those obtained by measuring fluorescence intensity 
of cell lysates (see Figure 3.10 b), in which an increase in relative EGFP expression of 0.3 and 
0.91 was observed after 3h and 6h post transfection, respectively, compared to cells that were 
not transfected.  
 
Concerning the cells transfected with AuNP@PEG@R4N
+
, the expression level remains 
unchanged when compared with the control cells, as shown by fluorescence microscopy (see 
Figure 3.10a) and by measuring the fluorescence of cells lysates (see Figure 3.10b). These 
results were not surprising because 3h and 6h post-transfection may not be enough time for the 
AuNPs complex to overcome the several barriers related to gene delivery vectors. Thus, the 
EGFP expression was assessed at 12h, 24h and 48h after transfection (see Figure 3.11).  
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Figure 3.11 – (a) Images obtained by fluorescence microscopy (scale bar, 50 m) of HCT-116 cells 
transfected with EGFP expression vector, using Lipofectamine 2000 and AuNP@PEG@R
4
N
+
@pEGFP, 
after 12h and 24h incubation; (b) Relative expression of EGFP was assessed by fluorescence 
spectroscopy, 12h, 24h and 48 h after transfection HCT-116 cells with 1 g of the EGFP expression 
vector, using Lipofectamine 2000 and AuNP@PEG@R
4
N
+
@pEGFP. Not transfected cells and with 
AuNP@PEG@R
4
N
+ 
were used as control. 
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Images acquired 12h and 24h after transfection of cells with the EGFP expression vector using 
Lipofectamine 2000 clearly showed efficient expression of the reporter gene (see Figure 3.11a). 
The images taken between 3 and 24h showed a trend, in which it was possible to confirm that 
the longer the incubation time, the higher the level of EGFP expression. This trend was also 
observed when fluorescence intensity of the cell lysates was acquired at 12h and 24h (Figure 
3.11 b), in which relative expression of EGFP increased 4 fold between 6h and 12h, and 2 fold 
between 12h and 24h, i.e., between 3h and 24h it was observed a 17 fold increase.  Curiously, 
the relative expression of EGFP decreases 48h post transfection but this can be explained by 
the cytotoxicity induced by Lipofectamine, which is known to cause toxicity to cells, and 
consequently the number of cells available to express EGFP decrease. Furthermore, this is a 
transient transfection in which plasmid does not replicate inside cells. Thus, plasmid gets diluted 
with cell division. 
 
Regarding cells transfected with AuNP@PEG@R4N
+
@pEGFP, these showed negligible EGFP 
expression 12h post transfection, when compared with non-transfected cells and cells incubated 
with AuNP@PEG@R
4
N
+
. The relative expression of EGFP 24h after being transfected 
increased 3.34 times, whereas using Lipofectamine as gene delivery, the expression increased 
17 times relatively to non-transfected cells. Both Lipofectamine and 
AuNP@PEG@R4N+@pEGFP carry the same amount of plasmid (1 g), but Lipofectamine 
showed better transfection efficiency.  
 
Although a low level of EGFP expression was achieved 24h after transfection with AuNP 
complexes, as shown by the fluorescence intensity of cell lysates (Figure 3.11b), the image 
corresponding to this assay in Figure 3.11a, did not clearly show an increase in the expression 
level relative to the image of control cells (non-transfected) acquired in the EGFP channel. 
These differences between both techniques may be due to their sensitivity. Due the barriers 
associated to non-viral gene delivery, there are several reasons that can explain this 
ineffectiveness of this AuNP-based gene delivery system. Thus, it was necessary to assess the 
internalization of AuNP complexes by cells, to better understand the system and further on the 
reasons for the low EGFP expression on transfected cells. 
 
3.3.3 EVALUTION OF NANOCONJUGATE UPTAKE BY PCR 
 
As mentioned above, a low level of EGFP expression was detected by fluorescence 
spectroscopy (relative EGFP expression increased ~3 times) which was not clearly observed in 
images acquired with fluorescence microscope, when transfection were performed with the            
AuNP-based formulation developed. Thus, to obtain more detailed information about cellular 
uptake of the AuNP-based formulation by cells, a PCR was performed with the total DNA 
extracted from non-transfected cells, from cells that had been incubated with 
AuNP@PEG@R4N
+
 (negative controls), from cells transfected with EGFP using Lipofectamine 
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2000 (positive control), and from cells incubated with AuNP@PEG@R4N
+
@pEGFP. The uptake 
was studied at different incubation times from 3h to 24h. As an internal PCR control the FTO 
gene (housekeeping gene) was used. 
 
The resulting PCR products, originating using the extracted DNA as template were analyzed in 
a 1% agarose gel electrophoresis and are shown in Figure 3.12.  
 
 
 
 
 
Figure 3.12 – Agarose gel electrophoresis (1%, 1x TAE, 60V 1h30) showing the amplification of EGFP 
gene using extracted DNA from transfected and non-transfected cells as template. (a) Lane 1 and 20 – 
ladder; lane 2 and 3 – control and EGFP plasmid amplified; lane 4 - 7 – 3h post transfection: cells, 
Lipofectamine@pEGFP, AuNP@PEG@R4N
+
, AuNP@PEG@R4N
+
@pEGFP, respectively; lane 8 -11 – 6h 
post transfection in same order described previously; lane 12 - 15 – 12h post transfection in same order 
described previously; lane 16 - 19 – 24h post transfection in same order described previously; (b) 
Amplification of FTO used as internal control. Lane 2 – control; Lane 3 – 6 – 3h post transfection: cells, 
Lipofectamine@pEGFP, AuNP@PEG@R4N
+
, AuNP@PEG@R4N
+
@pEGFP, respectively; lane 7 – 10 – 
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6h post transfection in same order described previously; lane 11 – 14 – 12h post 12h post transfection in 
same order described previously; lane 15 – 19 – 24h post transfection in same order described previously. 
 
The cellular uptake of the EGFP expression vector, monitored by electrophoretic analysis in 
agarose gel of the PCR products using as template the DNA extracted from transfected cells, 
revealed AuNP complexes into the cells 3h after transfection. Once plasmid alone has no ability 
to enter the cells, due their negative charge which makes it impossible penetrate the cell 
membrane, it is possible to conclude that the AuNP-based formulation developed can enter into 
the cells. Moreover, the internalization of the EGFP vector was not only detected at 3h 
incubation, as well as in the range 3 – 24h. However, at 24h post transfection with 
AuNP@PEG@R4N
+
@pEGFP (lane 19), the decrease of the intensity of the band can be 
indicative that some plasmid has already been diluted. This may have occurred because this 
was a transient transfection in which the plasmid was not integrated into the genome. Thus, the 
plasmid was diluted when cells were divided. However, this is not quantitative PCR.  
 
Once inside the cells, this delivery vector based on AuNPs overcomes one of the barriers in 
gene delivery, the cellular uptake. The ability of the nanocarrier to cross the cell membrane may 
be due to the effect of quaternary ammonium groups, which are responsible for the binding of 
plasmid to the nanocarrier but also, for establishing an electrostatic interaction with the cell 
membrane aiding in the internalization of the complex. Thus, in regard to cellular uptake, the 
delivery vector based on AuNPs was as efficient as Lipofectamine 2000. 
 
With these results, it is possible to conclude that the size of the AuNP complexes (113.5 nm 
0.8) is not an issue in cellular uptake. Futhermore, it was reported that the use of larger 
particles, contribute to a major gene delivery in cytoplasm, due to its long residence time in this 
compartment, avoiding rapid lysosomal degradation (Rejman et al. 2004). With a size of 113.5 
nm, the nanocarrier may be internalized through an endocytic process, since this process can 
be achieved with particles up to 150 nm. 
 
Once internalized, the plasmid must overcome other barriers, such as endo-lysosomal 
entrapment and release, cytosolic sequestration, nuclear entry and metabolic degradation, 
which reduce the efficiency of gene transfer. Furthermore, it is estimated that at least 10
5
 
plasmids per cell are required in the extracellular compartment to ensure that a few DNA 
molecules are taken up into the nucleus (Lechardeur et al. 2005). Facing these problems, it was 
not surprising the results related to EGFP expression obtained by fluorescence microscopy and 
fluorescence spectroscopy, since the formulation developed was not functionalized with specific 
sequences or proteins/peptides that can help to overcome these barriers.  
 
A studied achieved by Boyoglu et al., reported that AuNPs with sizes of 25 nm and 50 nm 
accumulated around the nucleus and remained in cytoplasm, after 1h incubation (Boyoglu et al. 
2013). This barrier was overcome in the work developed by Kang et al., where they used 30 nm 
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AuNPs functionalized with nuclear localization signal (NLS) peptide, which are capable to bind 
specifically to nuclear membrane  and must have facilitated a higher amount of AuNPs entry 
into the nucleus (Kang et al. 2010). Since it has been reported that quaternary ammonium 
groups have a possible proton-sponge effect, which could be responsible for endosome release 
of the entrapped nanocarrier (Yezhelyev et al. 2008), it was assumed that the inability of the 
AuNP-based formulation developed to successfully deliver the EGFP expression vector was not 
due to the inability of the nanocarrier to escape from the endosome. Furthermore, in images 
acquired with blue channel, where it was possible to see the nucleus stained with DAPI, it was 
observed some black spots over and around the nucleus, whereas in control cells and 
transfected with Lipofectamine 2000 these black spots were not observed (see section A3 in 
Appendix). This may suggest that some of the internalized AuNPs accumulated around the 
nucleus. What is not possible to conclude is whether the plasmid remains linked to the AuNP 
nanocarrier or if the pDNA was released from the AuNP complex. 
 
Thus, it was considered that the two major challenges to successfully achieve the transfection 
were the trafficking of plasmid through the cytoplasm and nuclear entry. Moreover, it has been 
estimated that the half-life of naked plasmid DNA in the cytoplasm of cells ranges between 50 
minutes and 5h. In a typical 24h transfection, assuming an average half-life of 3h, if the plasmid 
does not enter quickly into the nucleus, less than 0.4% of the input DNA would remain by 24h 
(Vaughan et al. 2006). However, at 24h post transfection it was still possible to confirm the 
presence of the plasmid in cells (see Figure 3.12a). This suggests that the plasmid was 
subjected to a protection which could be conferred, once again, by the quaternary ammonium 
groups. 
 
The formulation based on the gold nanoparticles developed, as well as the plasmid, had limited 
access to the nucleus due to the restriction posed by the nuclear membrane. The mechanism of 
entry of the exogenous material into the nucleus is not yet fully understood. Furthermore, this 
process depends on the transfection technique and the delivery vectors. In the most commonly 
used transfection methods (e.g using lipoplexes), exogenous DNA gains access to the nucleus 
by traveling along microtubules or during cell division, since nuclear pores only allow the entry 
of molecules up to 30 nm (Lechardeur et al. 2005, Ondrej et al. 2007, Vaughan & Dean 2006). 
 
Facing these issues, some hypothesis can explain why the plasmid DNA does not reach into 
the nucleus or just a low copie number can gain access to the nucleus. In case the plasmid 
does not dissociate from the nanocarrier, one explanation could concern the size of the 
nanocarrier. It is known that the nuclear pore complexes can be expanded up to 30 nm, so the 
nanocarrier could be too large to pass through nuclear pore complex. In case plasmid 
dissociated from the nanocarrier before entering the nucleus, plasmid entry into the nucleus 
becomes a challenge once in the absence of mitosis, the nuclear membrane remains largely 
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impermeable to plasmids (Vaughan et al. 2006). At last, if we consider that plasmid reach the 
nucleus, it is possible that the number of copies that can entry the nucleus is too low. 
 
To conclude, it was shown that it was possible bind the EFGP expression vector to AuNPs 
conjugated with PEG and quaternary ammonium groups and overcome one of the barriers 
associated to non-viral gene delivery vectors - cell uptake. 
 
3.4 TOXICITY ASSESSMENT OF AuNP-BASED FORMULATION 
 
To characterize the system effects in terms of cell viability, a MTS assay was performed, which 
determines mitochondrial activity in living cells. As shown in Figure 3.13, no cell viability 
changes were detected up to 48h incubation for AuNP-based formulations. It would be expected 
some toxicity of the AuNP@PEG@R4N
+
@pEGFP, due to the quaternary ammoniums once 
these groups have strong interaction with the cell surface. However, no toxicity was observed 
which constitute a great advantage relative to Lipofectamine 2000. 
 
However, significant decrease in cell viability in cells transfected with Lipofectamine was 
observed, which caused toxicity for 48 % of the cells. This can explain the low expression level 
of EGFP shown in Figure 3.11b, after 48h incubation of cells with Lipofectamine 2000. These 
types of cationic liposomes are already known to cause toxicity in cells and despite their great 
transfection efficiency, they cannot be deployed as non-viral gene delivery vectors for 
therapeutic approaches due their cytotoxicity. 
 
Figure 3.13 – Cell viability of HCT-116 cells after transfection with AuNPs-based formulations and 
Lipofectamine 2000, at 48 h of incubation.  Negligible influence in cell viability is observed for all 
nanoconjugates tested when compared to untreated cells (control). 
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Although it has not been proved that the delivery vector developed can be used successfully as 
non-viral gene delivery vector due the ineffective transfection, this formulation based on AuNPs 
still had advantages when compared with cationic vectors, such as liposomes. Among these 
advantages are the lack of cytotoxicity, showed by the MTS assay, and the possibility of 
vectorization using antibodies, peptides, proteins that can help to overcome some of the 
barriers associated with gene delivery, whereas the gene delivery vectors, such as liposomes, 
make use of only non-specific mechanisms. 
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4. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
In this work it was proposed to design a non-viral gene delivery vector based in AuNPs capable 
to transfect plasmid DNA in a cancer cell line. The biocompatibility of the system was improved 
by attaching 4300  114 PEG chains/AuNP. Furthermore, this group provides a moiety 
(carboxyl group) to bind quaternary ammonium groups, in which it was possible to link the 
EGFP expression vector via electrostatic interactions. The system was characterized by UV-vis 
spectroscopy, DLS and electrophoretic mobility. UV-vis spectroscopy allowed evaluation of the 
shift on SPR, which changes in function of the environment surrounding AuNPs. Thus, a SPR 
shift to a greater wavelength was indicative of functionalization and this was followed by the 
increase of the hydrodynamic diameter measured by DLS. Thus, it was observed a red-shift of 
the SPR from 521 to 533 nm since citrate-capped AuNPs to AuNP@PEG@R4N
+
@pEGFP.  The 
cellular uptake is more challenging to larger nanoparticles, however the size of the formulation 
developed (AuNP@PEG@R4N+@pEGFP) determined by DLS, 113.5  0.8 nm, did not appear 
to be a problem, since it could be internalized 3h post transfection. 
 
The non-viral delivery vector developed that has some limitations that can be overcome with 
some optimizations, had shown great potential to be a viable alternative to the available 
methods, such as Lipofectamine. The results obtained for the cellular uptake, showed that the 
developed system is as effective as Lipofectamine, revealing a cellular uptake 3h post 
transfection. Furthermore, it was possible to conclude that up to 24h there was still DNA present 
within the cell and it was not totally degraded, which indicates that this is subject to some kind of 
protection. 
 
The methods used to assess EGFP expression, fluorescence microscopy and spectroscopy, 
revealed a low expression EGFP expression in cells transfected with AuNP-based formulation 
24h post transfection. This can be probably due to the inability of the plasmid enter the nucleus 
or the low copy number of plasmid that can reach the nucleus. Since EGFP expression was not 
successfully achieved, some optimizations of the system and/or transfection procedure are 
needed. Once it has been proposed that the major barrier is the entry into the nucleus, it is 
proposed a new design of the delivery system by functionalization with nuclear localization 
signal peptides that are known to facilitate nuclear entry. Another method that can be used to 
promote EGFP expression is inducing this with IPTG. Alternatively, the intracellular trafficking of 
the formulation and pDNA could be followed by recording TEM images, in order to understand 
the principal limitation of the formulation once inside the cells. If the expression was achieved, 
this could be enhanced through vectorization of the formulation with e.g. EGFR (epidermal 
growth factor receptor) antibody. EGFR is a transmembrane tyrosine kinase receptor that is 
overexpressed in multiple cancer types, especially colorectal cancer, and appears to promote 
solid tumor growth (Krasinskas 2011). Once successfully achieved EGFP expression, 
quantitative real-time PCR must be performed to evaluate expression of EGFP. 
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Regarding to cytotoxicity, 48h after exposure of HCT-116 cells to both AuNP-based formulation 
and Lipofectamine 2000, significant differences were observed. Lipofectamine 2000 caused 
toxicity to 50 % of the cells, while AuNP-based formulation showed no toxicity to cells. In a 
future work, it would be desirable determine the cell viability in shorter incubation times. 
 
At last, facing the problems inherent to intracellular trafficking of non-viral delivery vectors, is 
suitable to say that formulation developed here is more suitable to use in mechanisms that do 
not involve the nuclear entry, such as siRNA or antisense oligonucleotides. 
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6. APPENDIX 
 
A1. pVisionGFP-N Vector 
 
Figure A1 - Schematic representation of pVisionGFP-N Vector. 
 
 
A2. LYSIS SOLUTIONS TO PLASMID EXTRACTION  
 
Lysis I  
50 mM Glucose  
25 mM Tris-HCl pH 8  
10mM EDTA pH 8  
Sterilised by autoclaving at 110 ºC for 25 minutes and stored at 4ºC.  
 
Lysis II  
200 mM NaOH 
1% (w/v) SDS freshly prepared (room temperature).  
 
Lysis III 
3M sodium acetate (The pH was adjusted to 4.8 with glacial acetic acid)  
Stored at 4ºC and kept in ice during use. 
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A3. IMAGES ACQUIRED IN DAPI CHANNEL 24H POST TRANSFECTION 
 
 

 

 

Cells 
24 h post transfection 
Lipofectamine 
24 h post transfection 
AuNP@PEG@R4N+@pEGFP 
24 h post transfection 
AuNPs 
